<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="research-article" dtd-version="1.3" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Immunol.</journal-id>
<journal-title-group>
<journal-title>Frontiers in Immunology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Immunol.</abbrev-journal-title>
</journal-title-group>
<issn pub-type="epub">1664-3224</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fimmu.2026.1780720</article-id>
<article-version article-version-type="Version of Record" vocab="NISO-RP-8-2008"/>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Original Research</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Macrophage-derived CCL20 promotes abdominal aortic aneurysm progression via lymphocytes CCR6</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Ren</surname><given-names>Qingnan</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/3323918/overview"/>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &amp; editing</role>
</contrib>
<contrib contrib-type="author">
<name><surname>Sun</surname><given-names>Tianyong</given-names></name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/2603422/overview"/>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &amp; editing</role>
</contrib>
<contrib contrib-type="author">
<name><surname>Shen</surname><given-names>Song</given-names></name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &amp; editing</role>
</contrib>
<contrib contrib-type="author">
<name><surname>Cao</surname><given-names>Yuanbin</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
</contrib>
<contrib contrib-type="author">
<name><surname>Wei</surname><given-names>Li</given-names></name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
</contrib>
<contrib contrib-type="author">
<name><surname>Zhao</surname><given-names>Yang</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
</contrib>
<contrib contrib-type="author">
<name><surname>Wan</surname><given-names>Fengxin</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
</contrib>
<contrib contrib-type="author">
<name><surname>Sui</surname><given-names>Ping</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
</contrib>
<contrib contrib-type="author">
<name><surname>Xiao</surname><given-names>Ke</given-names></name>
<xref ref-type="aff" rid="aff3"><sup>3</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/1510615/overview"/>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
</contrib>
<contrib contrib-type="author">
<name><surname>Bai</surname><given-names>Hao</given-names></name>
<xref ref-type="aff" rid="aff4"><sup>4</sup></xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
</contrib>
<contrib contrib-type="author">
<name><surname>Guo</surname><given-names>Dachuan</given-names></name>
<xref ref-type="aff" rid="aff5"><sup>5</sup></xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
</contrib>
<contrib contrib-type="author">
<name><surname>He</surname><given-names>Qi</given-names></name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
</contrib>
<contrib contrib-type="author">
<name><surname>Zhi</surname><given-names>Mengfan</given-names></name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
</contrib>
<contrib contrib-type="author">
<name><surname>Yang</surname><given-names>Jianmin</given-names></name>
<xref ref-type="aff" rid="aff5"><sup>5</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/1290726/overview"/>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project-administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
</contrib>
<contrib contrib-type="author">
<name><surname>Jiang</surname><given-names>Jianjun</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project-administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Zhang</surname><given-names>Wencheng</given-names></name>
<xref ref-type="aff" rid="aff5"><sup>5</sup></xref>
<xref ref-type="corresp" rid="c001"><sup>*</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/1265656/overview"/>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project-administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &amp; editing</role>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Ding</surname><given-names>Xiangjiu</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff6"><sup>6</sup></xref>
<xref ref-type="corresp" rid="c001"><sup>*</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/1971548/overview"/>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project-administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &amp; editing</role>
</contrib>
</contrib-group>
<aff id="aff1"><label>1</label><institution>Department of Vascular Surgery, General Surgery, Qilu Hospital of Shandong University</institution>, <city>Jinan</city>, <state>Shandong</state>,&#xa0;<country country="cn">China</country></aff>
<aff id="aff2"><label>2</label><institution>Department of Health Care (Department of General Dentistry II), Human Microbiome, Shandong Key Laboratory of Oral Tissue Regeneration, Shandong Engineering Research Center of Dental Materials and Oral Tissue Regeneration, Shandong Provincial Clinical Research Center for Oral Diseases, School and Hospital of Stomatology, Cheeloo College of Medicine, Shandong University</institution>, <city>Jinan</city>, <state>Shandong</state>,&#xa0;<country country="cn">China</country></aff>
<aff id="aff3"><label>3</label><institution>Department of Clinical Laboratory, Qilu Hospital of Shandong University</institution>, <city>Jinan</city>, <state>Shandong</state>,&#xa0;<country country="cn">China</country></aff>
<aff id="aff4"><label>4</label><institution>Clinical Epidemiology Unit, Department of Nutrition, Clinical Research Center of Shandong University, Qilu Hospital of Shandong University</institution>, <city>Jinan</city>, <state>Shandong</state>,&#xa0;<country country="cn">China</country></aff>
<aff id="aff5"><label>5</label><institution>Department of Cardiology, State Key Laboratory for Innovation and Transformation of Luobing Theory, Key Laboratory of Cardiovascular Remodeling and Function Research of MOE, NHC, CAMS and Shandong Province, Qilu Hospital of Shandong University</institution>, <city>Jinan</city>, <state>Shandong</state>,&#xa0;<country country="cn">China</country></aff>
<aff id="aff6"><label>6</label><institution>Shandong Key Laboratory of Medicine and Prevention Integration in Rheumatism and Immunity Disease, Qilu Hospital of Shandong University</institution>, <city>Jinan</city>, <state>Shandong</state>,&#xa0;<country country="cn">China</country></aff>
<author-notes>
<corresp id="c001"><label>*</label>Correspondence: Wencheng Zhang, <email xlink:href="mailto:zhangwencheng@sdu.edu.cn">zhangwencheng@sdu.edu.cn</email>; Xiangjiu Ding, <email xlink:href="mailto:xiangjiu-ding@sdu.edu.cn">xiangjiu-ding@sdu.edu.cn</email></corresp>
</author-notes>
<pub-date publication-format="electronic" date-type="pub" iso-8601-date="2026-03-02">
<day>02</day>
<month>03</month>
<year>2026</year>
</pub-date>
<pub-date publication-format="electronic" date-type="collection">
<year>2026</year>
</pub-date>
<volume>17</volume>
<elocation-id>1780720</elocation-id>
<history>
<date date-type="received">
<day>04</day>
<month>01</month>
<year>2026</year>
</date>
<date date-type="accepted">
<day>16</day>
<month>02</month>
<year>2026</year>
</date>
<date date-type="rev-recd">
<day>10</day>
<month>02</month>
<year>2026</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2026 Ren, Sun, Shen, Cao, Wei, Zhao, Wan, Sui, Xiao, Bai, Guo, He, Zhi, Yang, Jiang, Zhang and Ding.</copyright-statement>
<copyright-year>2026</copyright-year>
<copyright-holder>Ren, Sun, Shen, Cao, Wei, Zhao, Wan, Sui, Xiao, Bai, Guo, He, Zhi, Yang, Jiang, Zhang and Ding</copyright-holder>
<license>
<ali:license_ref start_date="2026-03-02">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
<license-p>This is an open-access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License (CC BY)</ext-link>. The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p>
</license>
</permissions>
<abstract>
<sec>
<title>Introduction</title>
<p>Abdominal aortic aneurysm (AAA) is a chronic vascular disease marked by chronic inflammation and immune dysregulation. The C-C motif chemokine ligand 20 (CCL20) - C-C motif chemokine receptor type 6 (CCR6) axis modulates immune responses in vascular diseases, but its role in AAA remains unclear. This study investigates the involvement of the CCL20-CCR6 axis in AAA formation.</p>
</sec>
<sec>
<title>Methods</title>
<p>Single-cell RNA sequencing datasets and bulk RNA sequencing datasets were analyzed to assess cellular composition and transcriptional changes. Transcriptomic analysis, enzyme-linked immunosorbent assay, UK Biobank database analysis, CellChat analysis, immunofluorescence staining, and mouse models were employed to explore the CCL20-CCR6 axis in AAA.</p>
</sec>
<sec>
<title>Results</title>
<p>Substantial immune cell infiltration (T lymphocytes &amp; B lymphocytes) and loss of structural cells (fibroblasts, endothelial cells and smooth muscle cells) were identified using single-cell RNA sequencing datasets. Macrophage polarization was imbalanced, with enriched M1-like macrophages and elevated CCL20 secretion. Macrophages could promote the formation of AAA by recruiting a large number of immune cells via the CCL20-CCR6 axis. <italic>In vitro</italic>, CCL20 neutralization reduced immune cell recruitment; <italic>in vivo</italic>, the knockdown of this axis inhibited AAA progression.</p>
</sec>
<sec>
<title>Conclusions</title>
<p>Macrophage-derived CCL20 aggravates lymphocyte recruitment via the CCR6, promoting AAA progression. CCL20 may serve as a biomarker for AAA. Targeting the CCL20-CCR6 axis could inhibit immune recruitment and AAA progression.</p>
</sec>
</abstract>
<kwd-group>
<kwd>abdominal aortic aneurysm</kwd>
<kwd>C-C motif chemokine ligand 20</kwd>
<kwd>C-C motif chemokine receptor 6</kwd>
<kwd>CCL20-CCR6 axis</kwd>
<kwd>vascular disease</kwd>
</kwd-group>
<funding-group>
<funding-statement>The author(s) declared that financial support was received for this work and/or its publication. This work was supported by the projects funded by the Natural Science Foundation of Shandong Province (No. ZR2021MH316, ZR2024ZD23, and ZR2024QH226), the National Natural Science Foundation of China (No. 82401119), and the Postdoctoral Innovation Program of Shandong Province (No. 202003007).</funding-statement>
</funding-group>
<counts>
<fig-count count="7"/>
<table-count count="2"/>
<equation-count count="0"/>
<ref-count count="76"/>
<page-count count="19"/>
<word-count count="9844"/>
</counts>
<custom-meta-group>
<custom-meta>
<meta-name>section-at-acceptance</meta-name>
<meta-value>Inflammation</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="s1" sec-type="intro">
<label>1</label>
<title>Introduction</title>
<p>Abdominal aortic aneurysm (AAA) represents a progressive, life-threatening vascular condition characterized by irreversible dilation of the abdominal aorta, often culminating in rupture. Epidemiological data indicate an incidence of 2-8% among individuals over 65 years, with rupture-associated mortality reaching 24.5% despite advancements in endovascular repair (<xref ref-type="bibr" rid="B1">1</xref>&#x2013;<xref ref-type="bibr" rid="B3">3</xref>). Current clinical strategies rely predominantly on surgical interventions, as effective pharmacological therapies remain elusive, underscoring the urgent need for novel therapeutic targets to mitigate AAA progression and improve patient outcomes.</p>
<p>The pathogenesis of AAA is intricately linked to chronic inflammation, immune dysregulation, and structural degradation of the aortic wall. Key hallmarks include macrophage polarization, apoptosis of vascular smooth muscle cells (SMCs), and extracellular matrix remodeling (<xref ref-type="bibr" rid="B4">4</xref>&#x2013;<xref ref-type="bibr" rid="B6">6</xref>). Emerging evidence highlights the pivotal role of immune cells in driving this inflammatory cascade, with macrophages acting as key regulators (<xref ref-type="bibr" rid="B7">7</xref>&#x2013;<xref ref-type="bibr" rid="B9">9</xref>). Specifically, a variety of immune cells contribute to AAA progression in both human tissues and Angiotensin II (Ang II)-induced <italic>Apolipoprotein E-/- (ApoE-/-)</italic> mice models (<xref ref-type="bibr" rid="B10">10</xref>&#x2013;<xref ref-type="bibr" rid="B12">12</xref>), including macrophages (<xref ref-type="bibr" rid="B13">13</xref>&#x2013;<xref ref-type="bibr" rid="B15">15</xref>), T lymphocytes (T cells) (<xref ref-type="bibr" rid="B13">13</xref>, <xref ref-type="bibr" rid="B14">14</xref>), and B lymphocytes (B cells) (<xref ref-type="bibr" rid="B16">16</xref>, <xref ref-type="bibr" rid="B17">17</xref>). Macrophage-mediated immune regulation is pivotal in AAA progression (<xref ref-type="bibr" rid="B8">8</xref>, <xref ref-type="bibr" rid="B18">18</xref>), where M1 macrophage polarization and associated inflammation drive aneurysm formation via proteolytic enzymes and pro-inflammatory cytokines (<xref ref-type="bibr" rid="B18">18</xref>&#x2013;<xref ref-type="bibr" rid="B20">20</xref>). This polarization imbalance, triggered by environmental cues, sustains chronic inflammation and disrupts M1/M2 equilibrium (<xref ref-type="bibr" rid="B21">21</xref>, <xref ref-type="bibr" rid="B22">22</xref>).</p>
<p>Within AAA tissues, macrophages interact closely with T and B cells (<xref ref-type="bibr" rid="B17">17</xref>, <xref ref-type="bibr" rid="B23">23</xref>), facilitating immune cell communication and recruitment. Macrophages enhance T-cell infiltration through cytokine and chemokine signaling (<xref ref-type="bibr" rid="B24">24</xref>), while T cells, as predominant infiltrates in AAA (<xref ref-type="bibr" rid="B25">25</xref>), amplify progression via cytokine secretion (<xref ref-type="bibr" rid="B26">26</xref>&#x2013;<xref ref-type="bibr" rid="B28">28</xref>). B cells contribute to AAA progression through immunoglobulin production and cytokines (<xref ref-type="bibr" rid="B16">16</xref>, <xref ref-type="bibr" rid="B29">29</xref>), and their depletion in mice attenuates aneurysms by fostering immunosuppression (<xref ref-type="bibr" rid="B30">30</xref>, <xref ref-type="bibr" rid="B31">31</xref>). However, the full mechanisms of immune cell infiltration and interactions in AAA remain unclear (<xref ref-type="bibr" rid="B32">32</xref>), necessitating further investigation for deeper insights.</p>
<p>C-C chemokine ligand 20 (CCL20), also known as macrophage inflammatory protein-3&#x3b1;, is produced by multiple cell types in the vascular wall, including activated endothelial cells, SMCs, stromal cells, and infiltrating monocytes/macrophages, particularly under inflammatory conditions (<xref ref-type="bibr" rid="B33">33</xref>&#x2013;<xref ref-type="bibr" rid="B35">35</xref>). Through its interaction with its exclusive receptor, C-C motif chemokine receptor type 6 (CCR6), which is expressed on T cells, B cells, Natural Killer T (NKT) cells, and neutrophils (<xref ref-type="bibr" rid="B33">33</xref>, <xref ref-type="bibr" rid="B36">36</xref>, <xref ref-type="bibr" rid="B37">37</xref>), CCL20 mediates the recruitment of these immune cells to inflammatory sites (<xref ref-type="bibr" rid="B38">38</xref>, <xref ref-type="bibr" rid="B39">39</xref>). The CCL20-CCR6 axis has garnered significant interest in recent years, as evidenced by studies establishing its functional involvement in vascular pathologies (<xref ref-type="bibr" rid="B37">37</xref>, <xref ref-type="bibr" rid="B40">40</xref>, <xref ref-type="bibr" rid="B41">41</xref>). However, the relationship between the CCL20-CCR6 axis and the pathogenesis of AAA has yet to be fully understood.</p>
<p>This study integrates single-cell RNA sequencing datasets and bulk RNA sequencing datasets with experimental validations to reveal how macrophage polarization imbalances promote immune recruitment and inflammation via the CCL20-CCR6 axis. Overall, these findings offer novel perspectives on immune regulation in AAA, positioning the CCL20-CCR6 axis as a critical contributor to AAA progression. The intervention experiments are employed to investigate the role and mechanism of this axis in AAA progression, with the aim to provide valuable insights into the immune regulatory mechanisms and therapeutic potential of the CCL20-CCR6 axis in AAA pathogenesis and progression.</p>
</sec>
<sec id="s2" sec-type="materials|methods">
<label>2</label>
<title>Materials and methods</title>
<sec id="s2_1">
<label>2.1</label>
<title>Collection of human abdominal aortic tissue and peripheral blood samples</title>
<p>This study was conducted in accordance with the principles of the Declaration of Helsinki and received approval from the Ethics Committee of Qilu Hospital of Shandong University (Approval No.: KYLL-202503-09-046-1) for human samples. Written informed consent was obtained from all participants or the families of organ donors. Human abdominal aortic aneurysm (AAA) tissues were collected from six patients (4 males, 2 females; age range: 58&#x2013;71 years, mean: 65.83 years, median: 67.5 years, standard deviation(SD) = 5.27, interquartile range (IQR): 10) undergoing open surgical repair for AAA. Normal aortic tissues were obtained from five organ donors (5 males; age range: 51&#x2013;74 years, mean: 58 years, median: 56 years, standard deviation(SD) = 9.92, interquartile range (IQR): 17) who had died from cerebral hemorrhage. The demographics and comorbidities of the AAA patients and organ donors are summarized in <xref ref-type="supplementary-material" rid="SM1"><bold>Supplementary Table&#xa0;1</bold></xref>. These tissues were used for Western blot, immunohistochemistry (IHC), immunofluorescence (IF) staining and multiplex immunofluorescence (mIF).</p>
<p>Serum samples were collected from 80 patients with AAA and 79 healthy controls. Inclusion criteria for AAA patients included an AAA diameter exceeding 30 mm and a definite diagnosis of AAA confirmed by computed tomography angiography of the full aorta. Exclusion criteria for AAA patients encompassed false (infected, inflammatory, or traumatic) or dissected AAAs, those caused by genetic or connective tissue diseases such as Ehlers-Danlos syndrome or Marfan syndrome, a previous history of open or endovascular repair for AAAs, malignant tumors, acute or chronic infections, autoimmune diseases, and current use of antibiotics, anti-inflammatory drugs, or immunosuppressive therapy. The control group consisted of healthy individuals matched for age and gender. Serum samples from AAA patients were obtained from the Department of Vascular Surgery at Qilu Hospital of Shandong University, while those from controls were collected from the Department of Health Management Center at the same institution. Demographic and clinical information for both groups is summarized in <xref ref-type="supplementary-material" rid="SM1"><bold>Supplementary Table&#xa0;2</bold></xref>. All samples were stored at 4&#xb0;C until analysis.</p>
</sec>
<sec id="s2_2">
<label>2.2</label>
<title>Animal experiments</title>
<p>All animal procedures followed the National Institutes of Health <italic>Guide for the Care and Use of Laboratory Animals</italic> and were approved by the Experimental Animal Ethics Committee of Qilu Hospital of Shandong University (Approval No.: DWLL-2024-214). Eight-week-old <italic>ApoE<sup>-/-</sup></italic> male mice (C57BL/6J background) were obtained from Vital River Laboratory (China) and housed in pathogen-free conditions (12-h light/dark cycle, 24 &#xb1; 2&#xb0;C, 40 &#xb1; 5% humidity, five mice per cage). The mice were fed with a Western diet for four weeks to induce the formation of AAA. The western-style diet (high cholesterol diet) consisted of 17.3% protein, 21.2% fat, 48.5% carbohydrates, 0.2% cholesterol by mass, contributing 42% of total calories from fat (TD.88137, Envigo).</p>
</sec>
<sec id="s2_3">
<label>2.3</label>
<title>Angiotensin II-induced mice AAA model</title>
<p>To induce AAA, osmotic pumps (RWD Life Science, model 2004w, China) delivering Ang II (1000 ng/kg/min, Sigma-Aldrich, USA) were subcutaneously implanted in 8-week-old <italic>ApoE<sup>-/-</sup></italic> male mice (<xref ref-type="bibr" rid="B42">42</xref>). A total of 75 mice were randomly assigned to 5 experimental groups (n=15 per group): 1) Negative Control group; 2) AAV-shRNA (empty vector) group; 3) AAA model group; 4) AAV-shCCL20-treated AAA model group; and 5) AAV-CCR6-treated AAA model group. Mice were monitored daily for activity and mortality; aortic diameter was assessed weekly via Doppler ultrasound (FUJIFILM Visual Sonics, Japan). After 4 weeks, mice were euthanized with Carbon Dioxide (CO<sub>2</sub>), and tissues were harvested.</p>
</sec>
<sec id="s2_4">
<label>2.4</label>
<title>AAV-mediated CCL20/CCR6 intervention <italic>In Vivo</italic></title>
<p>To investigate the role of CCL20/CCR6 in AAA development, <italic>ApoE<sup>-/-</sup></italic> mice received tail vein injections of Adeno-Associated Viruses (AAV) carrying AAV9-cmv-shCCL20, AAV9-cmv-shCCR6, or a negative control (2&#xd7;10<sup>-11</sup>vector genomes). ShRNA sequences and serotype AAV9 viruses carrying these sequences or a negative control were purchased from Cyagen (China). The target shCCL20 sequence was: 5&#x2019;-CCAAAGCAGAACTGGGTGAAA-3&#x2019;; the target shCCR6 sequence was: 5&#x2019;-GATCCATGACTGACGTCTACCT-3&#x2019;.</p>
</sec>
<sec id="s2_5">
<label>2.5</label>
<title>Blood pressure measurement</title>
<p>Mouse systolic blood pressure, diastolic blood pressure, and heart rate were measured using a non-invasive tail-cuff system (BP-98A, Softron, Japan) pre- and post-model induction and during the modeling period.</p>
</sec>
<sec id="s2_6">
<label>2.6</label>
<title>Ultrasound examination</title>
<p>AAA was defined as a &#x2265; 50% dilation of the abdominal aortic diameter compared to the normal diameter in mice. Vascular Doppler ultrasound provided a rapid, effective, and non-invasive method for monitoring abdominal aortic diameter. Mice were anesthetized with 2% isoflurane, and hair was removed from the chest to abdomen using depilatory cream. Ultrasound coupling gel was applied to the abdomen of each mouse. Using an Doppler ultrasound system (Visual Sonics Vevo 2100, FUJIFILM, Japan) equipped with a 40 MHz transducer, the probe position was adjusted to identify the abdominal aorta via B-mode ultrasound. Color and spectral Doppler were used to confirm the blood direction and velocity consistent with aortic signals. The abdominal aortic diameter was measured three times per mouse via B-mode, color, and spectral Doppler.</p>
</sec>
<sec id="s2_7">
<label>2.7</label>
<title>Histopathological analysis</title>
<p>Mouse aortas were fixed in 4% paraformaldehyde for 24 hours, dehydrated through a graded ethanol series, cleared in xylene, embedded in paraffin, and sectioned into 5 &#x3bc;m serial slices. After standard deparaffinization and rehydration, the sections were processed as follows: Oil Red O staining for lipid deposition, hematoxylin and eosin staining (Sigma-Aldrich, USA) for histopathological changes and vascular integrity, elastic Van Gieson staining (Sigma-Aldrich, USA) for elastic fiber fragmentation, and Masson&#x2019;s trichrome staining (Solarbio, China) for collagen deposition. Stained sections were observed under a microscope (Nikon Eclipse E100, Japan) and analyzed quantitatively using ImageJ software (three fields per sample, double-blinded). Elastic degradation was graded as follows: Grade 1, intact with no degradation; Grade 2, mild elastic degradation; Grade 3, severe elastic degradation; Grade 4, aortic rupture.</p>
</sec>
<sec id="s2_8">
<label>2.8</label>
<title>Immunohistochemistry</title>
<p>IHC was performed using an IHC kit (Solarbio, China). Sections were deparaffinized, subjected to heat-induced ethylenediaminetetraacetic acid (EDTA) epitope retrieval, blocked with goat serum, and incubated overnight at 4&#xb0;C with primary antibodies: CD3 (Abcam, ab16669, 1:200, UK), CD19 (Abcam, ab245235, 1:200, UK), and CD68 (Abcam, ab282654, 1:150, UK). After washing with phosphate-buffered saline three times (5 minutes each), sections were incubated with biotinylated secondary antibodies, stained with 3,3&#x2019; -diaminobenzidine, and counterstained with hematoxylin. Stained sections were imaged under a microscope (Nikon Eclipse E100, Japan), and CD3+/CD19+/CD68+ cells were quantified by two independent pathologists blinded to the groups. Ten random high-power fields (50 &#xd7; magnification) per section were selected for positive cell counting.</p>
</sec>
<sec id="s2_9">
<label>2.9</label>
<title>Immunofluorescence staining and multiplex immunofluorescence</title>
<p>Human and mouse aortic tissues were fixed in 10% neutral buffered formalin, paraffin-embedded, and sectioned. Sections were deparaffinized in xylene and graded ethanol, subjected to heat-induced EDTA epitope retrieval, and blocked with goat serum for 1 hour. Sections. They were incubated overnight at 4&#xb0;C with primary antibodies: CD3 (Abcam, ab16669, 1:200, UK), CD19 (Abcam, ab245235, 1:200, UK), CCL20 (Proteintech, 26527-1-AP, 1:200, China), CD68 (Abcam, ab282654, 1:150, UK), CCR6 (Abcam, ab303672, 1:150, UK), CD204 (Abcam, ab314227, 1:150, UK), and CD86 (Cell Signaling Technology, 91882T, 1:100, USA). After washing, sections were incubated with secondary antibodies at room temperature for 1 hour: Alexa Fluor 488 anti-rabbit (Proteintech, RGAR002, 1:200, China), Alexa Fluor 594 anti-rabbit (Proteintech, RGAR002, 1:200, China), and Alexa Fluor 555 anti-rabbit (Proteintech, RGAR003, 1:200, China).</p>
<p>Multiplex immunofluorescence was performed on formalin-fixed, paraffin-embedded (FFPE) tissue sections using the Tyramide Signal Amplification (TSA) technique. Each round consisted of the following cycle: incubation with a primary antibody, followed by an HRP-conjugated secondary antibody, and then the corresponding TSA fluorescent dye (Opal series): CD68 (Genetech, GM087629, 1:200, China, PPD 520), CD86 (Cell Signaling Technology, 19589S, 1:100, USA, PPD 570), CD206 (Cell Signaling Technology, 24595, 1:100, USA, PPD 570), CD163 (Abcam, Ab182422, 1:150, UK, PPD 620), iNOS (Bioss Antibodies, BS-0162R,1:200, China, PPD 620), Arg1 (Abclonal biotechnology, A25808, 1:200, USA, PPD 620), F4/80 (Cell Signaling Technology, 70076S, 1:100, USA, PPD 520). Nuclei were counterstained with DAPI, and stained sections were examined under a confocal fluorescence microscope (Zeiss LSM 780, Germany).</p>
</sec>
<sec id="s2_10">
<label>2.10</label>
<title>Enzyme-linked immunosorbent assay</title>
<p>Serum CCL20 levels in AAA patients and healthy controls were quantified using a commercial ELISA kit (Proteintech, KE00149, China), following the manufacturer&#x2019;s protocol. Absorbance was measured at 450 nm.</p>
</sec>
<sec id="s2_11">
<label>2.11</label>
<title>Real-time quantitative PCR</title>
<p>Total RNA was extracted from tissues using a Tissue DNA Extraction Kit (TIANGEN, China). cDNA was synthesized, mixed with SYBR<sup>&#xae;</sup> Green (Accurate Biology, AG11701, China) and primers, and amplified per the manufacturer&#x2019;s instructions. Relative gene expression was calculated using the 2<sup>^&#x2212;&#x394;&#x394;Ct</sup> method with <italic>GAPDH</italic> as the reference gene. Primer sequences are shown in <xref ref-type="supplementary-material" rid="SM1"><bold>Supplementary Table&#xa0;3</bold></xref>.</p>
</sec>
<sec id="s2_12">
<label>2.12</label>
<title>Western blot analysis</title>
<p>Aortic tissue proteins were extracted using radioimmunoprecipitation assay lysis buffer, separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, and transferred to polyvinylidene fluoride membranes. Membranes were blocked with 5% skim milk, incubated overnight at 4&#xb0;C with primary antibodies (CCR6, abcam, ab227036 &amp; GAPDH, Proteintech, 60004-1-Ig), washed with Tris-Buffered Saline with Tween 20 buffer, incubated with secondary antibodies, and detected using an enhanced chemiluminescence reagent on a chemiluminescence imaging system (Azure Biosystems, USA). Quantification was performed using the ImageJ software for digital image analysis.</p>
</sec>
<sec id="s2_13">
<label>2.13</label>
<title>Transwell assay</title>
<p>A Transwell assay was performed to evaluate the chemotactic ability of macrophages toward B and T cells under inflammatory conditions. Mouse bone marrow-derived macrophages were stimulated with lipopolysaccharide (LPS) (100 ng/mL, L2880, Sigma-Aldrich, USA) for 24 hours, and the cell supernatant was collected. Using Transwell chambers (0.4 &#x3bc;m pore size, LabSelect, 14112), 2&#xd7;10<sup>5</sup> B or T cells were seeded in the upper chamber with serum-free medium, and supernatant was added to the lower chamber. After 48 hours, migrated cells were analyzed by flow cytometry.</p>
</sec>
<sec id="s2_14">
<label>2.14</label>
<title>Single-cell data analysis</title>
<p>Single-cell data used in this study were searched and downloaded from the Gene Expression Omnibus (GEO) database (<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/geo/">https://www.ncbi.nlm.nih.gov/geo/</ext-link>) under the accession numbers GSE166676 and GSE226492. The UMI expression matrix (10 &#xd7; files) with genes expressed in at least 5 cells and cells expressing at least 200 genes was loaded into Seurat (version 5.3.0) (<xref ref-type="bibr" rid="B43">43</xref>). Further cleaning steps were performed using nCount within twofold standard deviation, nFeature within twofold standard deviation, and mitochondria percentage below 15%. Mitochondrial genes, ribosomal genes, and the MALAT1 gene were then removed from the expression dataset to minimize technical noise during downstream normalization and dimensionality reduction. The SCTransform function was used for data normalization, scaling, and transformation, with S.Score and G2M.Score (calculated using the CellCycleScoring function based on S- and G2/M-phase-specific genes) included as covariates to regress out cell cycle-associated variation. DoubletFinder (version 2.0.6) was then used for the identification and removal of double cells (<xref ref-type="bibr" rid="B44">44</xref>). The R package scCDC (version 1.4) was used for the gene-specific contamination detection and correction in single-cell RNA-seq data (<xref ref-type="bibr" rid="B45">45</xref>).</p>
<p>After data merging, dimensionality reduction was performed using the RunPCA function, and the number of retained principal components was determined using a quantitative elbow-based approach. PCs were retained when individual variance explained fell below 5% while cumulative variance exceeded 90%, and when the change in variance explained between consecutive PCs was &lt;0.1%. The final PC number (<xref ref-type="bibr" rid="B14">14</xref>) was conservatively selected as the minimum value satisfying these criteria. To correct for batch effects between the two independent GEO datasets, Harmony integration (R package harmony, version 1.2.4) was then applied to the PCA embeddings using dataset identity as the batch variable. The Harmony-corrected low-dimensional representations were subsequently used for FindNeighbors and UMAP analyses.</p>
<p>The cell clusters were identified using the FindClusters function with a resolution of 0.7 and the Leiden algorithm. Marker genes for each cluster were identified using the FindAllMarkers function with the Wilcoxon rank-sum test under the following criteria: avg_log2FC &gt; 0.25, p_val_adj &lt; 0.05, pct1 &gt; 0.1, and pct2 &lt; 0.5. This analysis was performed for cluster marker identification and cell-type annotation purposes, rather than for donor-level differential expression inference. The AddModuleScore function was used to calculate module scores for predefined feature expression programs (e.g., M1-like or M2-like macrophage signatures) at the single-cell level.</p>
</sec>
<sec id="s2_15">
<label>2.15</label>
<title>Ro/e analysis</title>
<p>To assess the distributional preference of each cell cluster across different tissues or samples, we calculated the observed-to-expected ratio (Ro/e = Observed/Expected) using the R package Startrac (version 0.1.0) (<xref ref-type="bibr" rid="B46">46</xref>). In this analysis, cells were pooled within each condition, and the expected distribution was defined under the assumption of independence between cell cluster identity and tissue category, estimated from the marginal distributions of all pooled cells. Statistical significance was evaluated using Fisher&#x2019;s exact tests as implemented in Startrac, with Benjamini&#x2013;Hochberg correction applied for multiple testing. Cell clusters with adjusted P values &lt; 0.05 were considered to show significant deviation from the expected distribution.</p>
<p>A Ro/e value greater than 1 indicates that a given cell cluster is overrepresented in a particular tissue relative to the expected distribution, whereas a Ro/e value less than 1 denotes relative underrepresentation. We note that this Ro/e analysis was performed at the cell level and does not explicitly account for donor-level structure. Due to the limited number of donors and sparse representation of certain cell clusters across individual samples, donor-aware Ro/e analysis was not statistically feasible. Therefore, Ro/e results are presented as a descriptive summary of cell-type distribution patterns rather than as formal donor-level inference and should be interpreted with appropriate caution.</p>
</sec>
<sec id="s2_16">
<label>2.16</label>
<title>Cell-cell communication analysis using CellChat</title>
<p>Cell-cell communication analysis was performed using the R package CellChat (version 2.2.0) (<xref ref-type="bibr" rid="B47">47</xref>), which infers putative intercellular communication networks based on the expression of known ligand-receptor pairs. Normalized single-cell expression data and annotated cell types were used to estimate communication probabilities between cell populations. CellChat analysis was conducted on pooled single-cell datasets within each condition to characterize global communication patterns. Inferred interaction strength and pathway-level signaling patterns were quantified and visualized using the built-in CellChat functions, with the understanding that these measures reflect relative communication tendencies and may be influenced by cell-type abundance. Comparative analysis of signaling pathways between AAA and normal groups was performed to identify pathways showing condition-associated differences. The CCL signaling pathway was selected for focused analysis based on differential gene expression and pathway enrichment results, given its established relevance to inflammatory processes in AAA.</p>
</sec>
<sec id="s2_17">
<label>2.17</label>
<title>Bulk RNA-seq data analysis</title>
<p>The expression matrix data of two AAA-related bulk RNA-seq datasets (GSE183464 and GSE269845) were downloaded from the GEO database and processed independently using identical analysis pipelines. All analyses were performed in R (version 4.5.1). For each dataset, gene re-annotation and removal of low-expression genes were conducted prior to downstream analyses. Exploratory PCA was performed separately for each dataset for quality assessment. Differential expression analysis was then performed separately within each dataset using the limma-trend pipeline implemented in the limma (version 3.65.4) and edgeR (version 4.7.3) packages with disease status as the primary comparison (<xref ref-type="bibr" rid="B48">48</xref>, <xref ref-type="bibr" rid="B49">49</xref>). Differentially expressed genes were visualized using volcano plots. Genes that were consistently upregulated or downregulated in both datasets were considered AAA-associated differentially expressed genes. Functional enrichment analyses, including GO and KEGG enrichment based on the overlapping DEGs, as well as GSEA based on the logFC values of all genes, were performed using the clusterProfiler package (version 4.17.0) (<xref ref-type="bibr" rid="B50">50</xref>).</p>
</sec>
<sec id="s2_18">
<label>2.18</label>
<title>Immune cell deconvolution using CIBERSORTx</title>
<p>Immune cell composition in bulk RNA-seq samples was estimated using the CIBERSORTx method (<xref ref-type="bibr" rid="B51">51</xref>), a computational framework for digital cytometry based on gene expression signatures. Normalized gene expression matrices were uploaded to the CIBERSORTx web portal (<ext-link ext-link-type="uri" xlink:href="https://cibersortx.stanford.edu/index.php">https://cibersortx.stanford.edu/index.php</ext-link>), and the LM22 signature matrix was used to quantify the relative fractions of 22 immune cell types. Statistical significance of each cell-type proportion was assessed using 1000 permutations, and samples with <italic>P</italic> &lt; 0.05 were considered reliable for downstream analysis. Fractional abundances were further analyzed and visualized using R to compare immune cell composition across groups or conditions.</p>
</sec>
<sec id="s2_19">
<label>2.19</label>
<title>ScRNA-seq phenotype association using SCISSOR</title>
<p>Phenotype-associated single-cell populations were identified using the SCISSOR algorithm by the R package Scissor (version 2.0.0) (<xref ref-type="bibr" rid="B52">52</xref>), which integrates single-cell RNA-seq data with bulk phenotypic information (AAA and normal group). Each cell was assigned a score reflecting its association with the phenotype, and cells with significant positive or negative associations were selected for downstream analyses. Associated subpopulations were visualized using UMAP and heatmaps to highlight their distribution within the single-cell landscape.</p>
</sec>
<sec id="s2_20">
<label>2.20</label>
<title>Flow cytometry</title>
<p>Cells were centrifuged at 300 &#xd7; g for 5 minutes at 4&#xb0;C. The resulting cell pellet was resuspended in a buffer containing 0.5% bovine serum albumin. Cell viability and count were determined using trypan blue exclusion and an automated cell counter (Countess, Life Technologies, USA). Anti-CD16/CD32 antibody (BioLegend, 101302, USA) was added and incubated at room temperature for 10 minutes to minimize non-specific binding. Subsequently, cells were stained with fluorochrome-conjugated antibodies: FITC anti-mouse CD3 (BioLegend, 100203, USA), PE anti-mouse F4/80 (eBioscience, 12-4801-82, USA), and FITC anti-mouse CD19 (BioLegend, 115507, USA). Data were analyzed using FlowJo software.</p>
</sec>
<sec id="s2_21">
<label>2.21</label>
<title>Analysis of the UK biobank database</title>
<p>The UK Biobank received ethical approval from the North West Multi-Centre Research Ethics Committee (REC reference: 16/NW/0274). All participants provided informed consent to participate. The present analyses were conducted under UK Biobank application number 151350.</p>
<p>From a total of 502,128 participants in the UK Biobank, we excluded 450,068 individuals with missing data on the CCL20 protein level. After further excluding those with a baseline abdominal aortic aneurysm, the final analytical cohort comprised 52,017 individuals. This cohort was used to assess the association between circulating CCL20 levels at baseline and the risk of incident AAA. The baseline CCL20 levels were compared between participants who developed incident AAA and those who did not using a t-test. Multivariable Cox regression models were used to estimate hazard ratios (HR) and 95% confidence intervals (CI) for the association between circulating CCL20 level and risk of incident AAA. Multivariable-adjusted model was adjusted for age, sex, ethnicity, educational attainment, socioeconomic deprivation, body mass index, smoking status, alcohol drinking, healthy diet, leisure time physical activity, diabetes, hypertension, and hypercholesterolemia.</p>
</sec>
<sec id="s2_22">
<label>2.22</label>
<title>Statistical analysis</title>
<p>Statistical analyses were performed using GraphPad Prism 8.0 and R 4.5.1 in this study. <italic>In vitro</italic> and <italic>in vivo</italic> results are presented as mean &#xb1; standard error of the mean. Student&#x2019;s t-test (normal data) or Wilcoxon test (non-normal data) was performed to compare the means between two groups. Multiple group comparisons were conducted by one-way or two-way analysis of variance (ANOVA). Correlation analysis was performed using the Spearman method by the R package ggstatsplot (version 0.13.1). Statistical graphs were visualized by GraphPad Prism 9.5 or the R package ggplot2 (version 3.5.2). <italic>P</italic> &lt; 0.05 was considered significant. Details of the statistical analysis were mentioned in each Figure legend.</p>
</sec>
</sec>
<sec id="s3" sec-type="results">
<label>3</label>
<title>Results</title>
<sec id="s3_1">
<label>3.1</label>
<title>Immune cell infiltration and structural cell depletion in AAA</title>
<p>To examine the transcriptional landscape of the human abdominal aorta and determine cellular alterations in AAA tissues, two single-cell RNA-seq datasets (GSE166676: 2 normal, 4 AAA samples; GSE226492: 3 normal, 3 AAA samples) were downloaded from the Gene Expression Omnibus (GEO) database. After quality control and batch effects correction, 67,656 cells were obtained (39,782 normal, 27,874 AAA; <xref ref-type="supplementary-material" rid="SM1"><bold>Supplementary Figures&#xa0;1A&#x2013;C</bold></xref>). All of the cells were categorized into 16 clusters (<xref ref-type="supplementary-material" rid="SM1"><bold>Supplementary Figures&#xa0;1D&#x2013;F</bold></xref>). Based on cellular marker genes, cells were clustered and further annotated into 11 distinct main types (<xref ref-type="fig" rid="f1"><bold>Figures&#xa0;1A, B</bold></xref>).</p>
<fig id="f1" position="float">
<label>Figure&#xa0;1</label>
<caption>
<p>Immune Infiltration and Structural Cells Depletion in AAA. <bold>(A)</bold> Uniform manifold approximation and projection (UMAP) map of 11 annotated cell clusters of single-cell data (all cells). <bold>(B)</bold> Expression of the marker genes in each major cell type. <bold>(C, D)</bold> UMAP and cell composition of the normal and AAA groups. <bold>(E)</bold> The proportion of altered 11 cell types between the normal and AAA groups. <bold>(F)</bold> Ratio of observed to expected (Ro/e) analysis for cell types in different groups with cell proportion bar plot visualized at right; <bold>(G, H)</bold> The statistics test of the proportion of altered structural cell types and immune cell types in each sample. <bold>(I)</bold> Representative images of IHC of B cells (CD19) and T cells (CD3) in the the normal (n=5) and AAA group (n=6). Scale bar: 100 &#x3bc;m. <bold>(J)</bold> Representative images of IF staining of B cells (CD19, red) and T cells (CD3, yellow) in the the normal (n=5) and AAA group(n=6); nuclei were stained with DAPI (blue). Scale bar: 50 &#x3bc;m. ****<italic>P</italic> &lt; 0.0001.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-17-1780720-g001.tif">
<alt-text content-type="machine-generated">Panel A displays a UMAP plot of 67,656 single cells, color-coded by cell type with a summary table for normal and AAA samples. Panel B presents a dot plot heatmap comparing gene expression across cell types. Panel C shows a UMAP of normal cells and a donut chart indicating cell type proportions. Panel D displays the UMAP and donut chart for AAA cells. Panel E provides a stacked bar comparison of cell type proportions between groups. Panel F contains a bar chart with role indices of cell types. Panels G and H include bar graphs of cell type proportions with statistical significance. Panel I features stained tissue sections for CD19 and CD3 in normal and AAA samples with quantification graphs. Panel J offers immunofluorescence images, comparing normal and AAA tissue, highlighting cell type markers.</alt-text>
</graphic></fig>
<p>To detect the variability in the proportions of different cell types across groups, we calculated the proportions of all cells from the two groups. Compared with the normal group, the proportion of structural cells was substantially decreased in AAA tissues, including fibroblasts (from 34.63% to 11.52%), endothelial cells (from 17.59% to 3.89%), and SMCs (from 12.95% to 1.66%) (<xref ref-type="fig" rid="f1"><bold>Figures&#xa0;1C&#x2013;E, G</bold></xref>). Conversely, immune cells such as T cells (from 3.84% to 22.35%), B cells (from 1.92% to 29.59%), and NKT cells (from 2.39% to 7.14%) were significantly enriched (<xref ref-type="fig" rid="f1"><bold>Figures&#xa0;1C&#x2013;E, H</bold></xref>), indicating substantial immune cell infiltration and immune microenvironment remodeling in AAA, while the proportion of macrophages showed minimal change (from 13.14% to 13.54%) (<xref ref-type="fig" rid="f1"><bold>Figures&#xa0;1C&#x2013;E</bold></xref>).</p>
<p>To further evaluate the tissue distribution preferences of different cell types, we performed Ro/e preference analysis. The results demonstrated that structural cells (fibroblasts, endothelial cells, and SMCs) were less prevalent in the AAA group compared to the normal group (<xref ref-type="fig" rid="f1"><bold>Figure&#xa0;1F</bold></xref>), whereas immune cells (T cells, B cells, and NKT cells) exhibited preferential enrichment in AAA tissues (<xref ref-type="fig" rid="f1"><bold>Figure&#xa0;1F</bold></xref>). IHC and IF staining of human aortic tissues further confirmed the enrichment of T cells and B cells (<xref ref-type="fig" rid="f1"><bold>Figures&#xa0;1I, J</bold></xref>; <xref ref-type="supplementary-material" rid="SM1"><bold>Supplementary Figures&#xa0;1G, H</bold></xref>). Consistent with prior research (<xref ref-type="bibr" rid="B53">53</xref>), findings revealed a profound cellular imbalance in AAA tissues, characterized by extensive immune cell infiltration (T cells and B cells) and loss of structural cells (fibroblasts, endothelial cells, and SMCs).</p>
</sec>
<sec id="s3_2">
<label>3.2</label>
<title>Inflammatory and immune responses were activated in AAA</title>
<p>To investigate the transcriptomic signatures between AAA and normal tissues, two human bulk RNA-seq datasets (GSE183464 and GSE269845) were downloaded from the GEO database. Results of Principal component analysis (PCA) revealed significant transcriptomic heterogeneity between the groups (<xref ref-type="fig" rid="f2"><bold>Figures&#xa0;2A, B</bold></xref>). We then identified differentially expressed genes (DEGs) using the threshold described in the Methods section, comparing the AAA and normal groups in both datasets. Upregulated genes <italic>(e.g., C-C motif chemokine receptor 7 (CCR7), C-X-C motif chemokine receptor 4 (CXCR4), Cluster of Differentiation 79A (CD79A)</italic> were associated with immune responses, immune cell activation, and cell communication, whereas downregulated genes (e.g., <italic>Actin Alpha Cardiac Muscle 1 (ACTC1), Collagen, type IV, alpha 3 chain (COL4A3), Actinin, alpha 2 (ACTN2)</italic> were linked to vascular structure and cytoskeleton organization (<xref ref-type="fig" rid="f2"><bold>Figures&#xa0;2C, D</bold></xref>). A Venn diagram showed that 589 genes were consistently upregulated and 449 genes were consistently downregulated in the two datasets (<xref ref-type="fig" rid="f2"><bold>Figure&#xa0;2E</bold></xref>).</p>
<fig id="f2" position="float">
<label>Figure&#xa0;2</label>
<caption>
<p>Immune-Inflammatory Activation and Vascular Structural Disruption in AAA. <bold>(A, B)</bold> PCA plot of the bulk RNA-seq datasets GSE183464 and GSE269845. <bold>(C, D)</bold> The volcano plot of DEGs in the normal and AAA groups. <bold>(E)</bold> Venn diagram of co-expressing upregulated and downregulated DEGs in the two datasets. <bold>(F)</bold> Bubble plot of GO BP enrichment results for DEGs. <bold>(G)</bold> Bubble plot of enriched KEGG pathways for DEGs. <bold>(H, I)</bold> GSEA results based on KEGG identified activated and suppressed pathways in the normal and AAA groups. Categories with red dots (NES &gt; 0) showed the activated pathways in AAA group, while categories with blue dots (NES &lt; 0) showed the activated pathways in the normal group.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-17-1780720-g002.tif">
<alt-text content-type="machine-generated">Scientific figure presenting results from gene expression analyses between abdominal aortic aneurysm (AAA) and normal samples across two datasets. Panels A and B show PCA plots separating AAA and normal groups. Panels C and D are volcano plots of differentially expressed genes with labeled genes. Panel E shows overlapping gene sets in a Venn diagram. Panel F displays GO biological pathway enrichment with bubble plot. Panel G provides KEGG pathway enrichment comparing upregulated and downregulated genes. Panels H and I present gene set enrichment analysis (GSEA) plots for each dataset highlighting significantly enriched pathways.</alt-text>
</graphic></fig>
<p>Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment indicated upregulated genes were enriched in inflammatory processes, immune activation, and cytokine chemotaxis, while downregulated genes related to extracellular matrix degradation and smooth muscle contraction (<xref ref-type="fig" rid="f2"><bold>Figures&#xa0;2F, G</bold></xref>; <xref ref-type="supplementary-material" rid="SM1"><bold>Supplementary Figure&#xa0;2</bold></xref>). Gene set enrichment analysis (GSEA) confirmed immune-related pathways (e.g., B/T cell receptor signaling, cytokine-cytokine receptor interaction, chemokine signaling, and lipid metabolism) were significantly active in AAA; whereas pathways related to aortic structure (e.g., extracellular matrix-receptor interaction, SMC cytoskeleton, and vascular smooth muscle contraction) were suppressed (<xref ref-type="fig" rid="f2"><bold>Figures&#xa0;2H, I</bold></xref>). These results demonstrated that AAA tissues exhibited enhanced inflammatory and immune responses accompanied by the disruption of vascular wall integrity.</p>
</sec>
<sec id="s3_3">
<label>3.3</label>
<title>Macrophage polarization influenced the progression of AAA</title>
<p>To identify cell types associated with the progression of AAA and further explore their biological characteristics, the Scissor algorithm was performed using the datasets GSE183464 and GSE269845, respectively, and a higher proportion of Scissor+ cells was obtained in the AAA group (<xref ref-type="supplementary-material" rid="SM1"><bold>Supplementary Figures&#xa0;3A, B</bold></xref>). In terms of relative proportions, there are more Scissor+ cells in macrophages, and SMC exhibited the highest proportion of Scissor- cells (<xref ref-type="fig" rid="f3"><bold>Figures&#xa0;3A, B</bold></xref>), indicating that macrophages play a critical role in AAA pathogenesis. However, single-cell data analysis (<xref ref-type="fig" rid="f1"><bold>Figure&#xa0;1E</bold></xref>) and IHC staining (<xref ref-type="fig" rid="f3"><bold>Figure&#xa0;3C</bold></xref>) revealed no significant change in the proportion of macrophages between the AAA and normal groups.</p>
<fig id="f3" position="float">
<label>Figure&#xa0;3</label>
<caption>
<p>Macrophage Polarization Correlates with AAA Progression. <bold>(A, B)</bold> Results of AAA-related cells identification from single-cell datasets via Scissor algorithm by the bulk RNA-seq datasets GSE1834645 and GSE269845, respectively. <bold>(C)</bold> Representative images of IHC staining of macrophage cells (CD68) in the the normal (n=5) and AAA group(n=6). Scale bar: 100 &#x3bc;m. <bold>(D, E)</bold> CIBERSORTx was performed and calculated the relative composition of immune cell subsets between the normal and AAA group. <bold>(F)</bold> Signature Module Score of M1-like and M2-like macrophages in the normal and AAA groups. <bold>(G)</bold> Expression level of M1-like and M2-like macrophage signature genes in single-cell data in the normal and AAA groups. <bold>(H)</bold> Representative images of IF of M1-like macrophages marker (CD86, green) and M2-like macrophages marker (CD204, red) in the the normal (n=5) and AAA group (n=6); nuclei were stained with DAPI (blue), scale bar, 50 &#x3bc;m. *<italic>P</italic> &lt; 0.05, **<italic>P</italic> &lt; 0.01, ****<italic>P</italic> &lt; 0.0001.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-17-1780720-g003.tif">
<alt-text content-type="machine-generated">Panel A and B display UMAP plots with cell clustering and color-coded Scissor status, accompanied by bar graphs showing cell type proportions. Panel C presents CD68-stained histological sections comparing normal and AAA tissues with quantification graphs. Panels D and E show boxplots of cell composition differences between normal and AAA using CIBERSORTx analyses for two datasets. Panel F provides violin plots comparing M1 and M2 macrophage module scores between groups. Panel G includes a dot plot representing expression of macrophage signature genes in AAA and normal samples. Panel H consists of immunofluorescence images for CD68 and CD204 in normal and AAA tissues, labeled with DAPI.</alt-text>
</graphic></fig>
<p>CIBERSORTx was performed to investigate the difference in the composition of immune cell subsets between the AAA and normal groups, and the relative proportions of immune cell infiltration were calculated (<xref ref-type="supplementary-material" rid="SM1"><bold>Supplementary Figures&#xa0;3C, D</bold></xref>). Compared with the normal group, the AAA group showed a significant decrease in NK cells activated, monocytes, and M2 macrophages in GSE183464 (<xref ref-type="fig" rid="f3"><bold>Figure&#xa0;3D</bold></xref>). In GSE269845, the AAA group exhibited a significant decrease in macrophages M0, and macrophages M2 (<xref ref-type="fig" rid="f3"><bold>Figure&#xa0;3E</bold></xref>). The results demonstrated that the proportion of M2 macrophages was statistically significantly reduced in the AAA group of two datasets.</p>
<p>The single-cell datasets revealed that the M1-like macrophage signature module score was upregulated in the AAA group, while the normal group exhibited a higher M2-like macrophage module score (<xref ref-type="fig" rid="f3"><bold>Figure&#xa0;3F</bold></xref>). Furthermore, macrophages in the AAA group expressed elevated M1-like macrophage signatures, while the normal group exhibited higher expression of M2-like macrophage signatures (<xref ref-type="fig" rid="f3"><bold>Figure&#xa0;3G</bold></xref>). Additionally, Cluster of Differentiation 204 (CD204) (MSR1) was highly expressed in healthy human aortas, and a higher expression level of Cluster of Differentiation 86 (CD86) was observed in the AAA tissues (<xref ref-type="fig" rid="f3"><bold>Figure&#xa0;3H</bold></xref>; <xref ref-type="supplementary-material" rid="SM1"><bold>Supplementary Figures&#xa0;3E, F</bold></xref>). We further characterized macrophage polarization through multiplex immunofluorescence staining by identifying additional M1/M2 markers to provide a more comprehensive assessment of macrophage polarization. In human samples, macrophages with pro-inflammatory M1-like features were identified as CD68<sup>+</sup>CD86<sup>+</sup>iNOS<sup>+</sup>, and macrophages with anti-inflammatory M2-like features were identified as CD68<sup>+</sup>CD163<sup>+</sup>CD206<sup>+</sup>, reflecting their functional polarization tendencies (<xref ref-type="supplementary-material" rid="SM1"><bold>Supplementary Figures&#xa0;3G, H</bold></xref>). Our results show that macrophages in AAA samples exhibited a stronger M1-like functional profile, indicating M1 polarization, while in normal samples, macrophages displayed higher expression of M2 markers, including CD68<sup>+</sup>CD163<sup>+</sup>CD206<sup>+</sup>. These findings indicated that the proportion of macrophages showed little change, while the imbalance between M1-like and M2-like macrophage polarization might influence the AAA progression.</p>
</sec>
<sec id="s3_4">
<label>3.4</label>
<title>Macrophages exhibited altered gene expression accompanied by abundant secretion of CCL20 in AAA</title>
<p>Macrophages have been shown to play a critical pathophysiological role in AAA progression (<xref ref-type="bibr" rid="B8">8</xref>, <xref ref-type="bibr" rid="B54">54</xref>). After identifying the imbalance of macrophage polarization between the normal and AAA groups, we investigated the gene expression in macrophages. DEG analysis was performed using the single-cell datasets on macrophages between the&#xa0;AAA and normal groups. Compared to the normal group, 139&#xa0;upregulated and 105 downregulated DEGs were obtained in AAA macrophages (<xref ref-type="fig" rid="f4"><bold>Figure&#xa0;4A</bold></xref>). GO term and KEGG pathway enrichment analysis demonstrated that the upregulated genes were significantly associated with biological processes, including chemotaxis, cell chemotaxis, immune and inflammatory response, and pathways including <italic>Tumor Necrosis Factor (TNF)</italic> signaling pathway, <italic>Peroxisome Proliferator-Activated Receptor (PPAR)</italic> signaling pathway, chemokine signaling pathway, cytokine-cytokine receptor interaction pathway, and so on (<xref ref-type="fig" rid="f4"><bold>Figures&#xa0;4B, C</bold></xref>). GSEA further confirmed that these processes and pathways were activated in the AAA group (<xref ref-type="fig" rid="f4"><bold>Figure&#xa0;4D</bold></xref>). RT-qPCR was performed to validate these findings in human AAA tissues. The results showed that expression of genes related to immune response and chemotaxis (<italic>Interleukin-1 &#x3b2; (IL-1&#x3b2;), Interleukin-8 (IL-8), and TNF-&#x3b1;</italic>) was elevated (<xref ref-type="fig" rid="f4"><bold>Figure&#xa0;4E</bold></xref>). Additionally, the expression levels of lipid metabolism-related markers (<italic>Acetyl-CoA Carboxylase 1 (ACC1)</italic>, <italic>Fatty Acid Synthase (FASN)</italic>, and <italic>PPAR-&#x3b3;</italic>) were elevated (<xref ref-type="fig" rid="f4"><bold>Figure&#xa0;4F</bold></xref>). Oil Red O staining also revealed notable lipid deposition in the aneurysm (<xref ref-type="fig" rid="f4"><bold>Figure&#xa0;4G</bold></xref>). These results demonstrated inflammatory and lipid accumulation features in macrophages of AAA.</p>
<fig id="f4" position="float">
<label>Figure&#xa0;4</label>
<caption>
<p>Macrophages Exhibit Altered Gene Expression and Secrete Abundant CCL20. <bold>(A)</bold> The volcano plot of DEGs of macrophages in the normal and AAA groups in GSE166676 and GSE226492. <bold>(B)</bold> Bubble plot of GO BP enrichment results for DEGs. <bold>(C)</bold> Bubble plot of enriched KEGG pathways for DEGs. <bold>(D)</bold> GSEA results based on KEGG identified activated and suppressed pathways of macrophages in the normal and AAA groups. Categories with red dots (NES &gt; 0) showed the activated pathways in AAA group, while categories with blue dots (NES &lt; 0) showed the activated pathways in the normal group. <bold>(E)</bold> The mRNA expression of IL-1beta, IL-8, TNF-&#x3b1; in normal and AAA tissues from human. <bold>(F)</bold> The mRNA expression of ACC1, FASN, and PPAR-&#x3b3; in human Normal and AAA groups. <bold>(G)</bold> Representative images of Oil red O staining of the normal (n=5) and AAA group (n=6). Scale bar:10, 25&#x3bc;m. <bold>(H)</bold> All up DEGs in the Cytokine-Cytokine receptor interaction pathway. <bold>(I)</bold> CCL20 expression in 11 cell types. <bold>(J)</bold> Representative images of IF co-localization of CCL20 (green) and macrophages (CD68, red). Nuclei were stained with DAPI (blue), scale bar, 50 &#x3bc;m. The synchronized fluctuations of CCL20 (green) and macrophages (CD68, red) curves indicated co-localization at these discrete sites. <bold>(K)</bold> CCL20 expression in 11 cell types between the normal group and AAA groups. <bold>(L)</bold> ELISA test of CCL20 in the normal group (n=79) and AAA group (n=80). <bold>(M)</bold> ROC curve comparing models for AAA diagnosis. The model achieved an area under the curve (AUC) of 0.7. <bold>(N)</bold> Representative images of IF of CCL20 (green) expression in the the normal (n=5) and AAA group (n=6). Nuclei were stained with DAPI (blue), scale bar, 50 &#x3bc;m. *<italic>P</italic> &lt; 0.05, **<italic>P</italic> &lt; 0.01, ***<italic>P</italic> &lt; 0.001, and ****<italic>P</italic> &lt; 0.0001.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-17-1780720-g004.tif">
<alt-text content-type="machine-generated">Scientific figure with multiple panels showing data on macrophage activity and cytokine involvement in abdominal aortic aneurysm (AAA) versus normal tissue; displays volcano plots, dot plots, bar graphs, gene set enrichment analysis, gene expression panels, histology and immunofluorescence images, ELISA quantification, and ROC curve, illustrating significant upregulation of inflammatory and chemotactic pathways in AAA, including elevated CCL20 expression and colocalization in tissue samples.</alt-text>
</graphic></fig>
<p>Given the significant enrichment observed (<xref ref-type="fig" rid="f4"><bold>Figures&#xa0;4B, C</bold></xref>), we investigated the cytokine-cytokine receptor interaction pathway and ranked the average log<sub>2</sub>FC values of the associated upregulated DEGs (<xref ref-type="fig" rid="f4"><bold>Figure&#xa0;4H</bold></xref>, <xref ref-type="supplementary-material" rid="SM1"><bold>Supplementary Figure&#xa0;4D</bold></xref>). Among these, Interleukin-1 &#x3b1; (IL-1&#x3b1;), C-X-C motif chemokine ligand 10 (CXCL10), and CCL20 were the top three elevated factors in macrophages from AAA. single-cell datasets revealed that CCL20 was primarily and highly expressed in macrophages across all 11 cell types analyzed (<xref ref-type="fig" rid="f4"><bold>Figure&#xa0;4I</bold></xref>). IF co-localization further confirmed that CCL20 is predominantly present in macrophages (<xref ref-type="fig" rid="f4"><bold>Figure&#xa0;4J</bold></xref>). Compared to the normal group, CCL20 expression in macrophages was significantly elevated in AAA tissues (<xref ref-type="fig" rid="f4"><bold>Figure&#xa0;4K</bold></xref>), which was also evident in the GSE183464 and GSE269845 datasets (<xref ref-type="supplementary-material" rid="SM1"><bold>Supplementary Figure&#xa0;4A</bold></xref>).</p>
<p>Considering the secretory nature of CCL20 and its previously validated diagnostic efficacy as a biomarker (<xref ref-type="bibr" rid="B55">55</xref>), serum samples were collected from 80 AAA patients and 79 healthy controls for ELISA analysis (<xref ref-type="supplementary-material" rid="SM1"><bold>Supplementary Table&#xa0;2</bold></xref>). The results indicated significantly higher CCL20 levels in AAA patients compared to healthy controls (<xref ref-type="fig" rid="f4"><bold>Figure&#xa0;4L</bold></xref>), with an AUC value of 0.7 (<xref ref-type="fig" rid="f4"><bold>Figure&#xa0;4M</bold></xref>).</p>
<p>To make an external validation, we analyzed the data from the UK Biobank. In the cohort of 52,017 participants, 329 incident AAA cases were identified during a median follow-up of 13.59 years. The demographic characteristics of participants were shown in <xref ref-type="table" rid="T1"><bold>Table&#xa0;1</bold></xref>. Multivariable Cox regression results showed that a per 1-SD increase in circulating CCL20 level was associated with increased risk of AAA. Compared to participants with the lowest quartiles (Q1) of CCL20, those with the highest quartiles (Q4) had a 44% increased risk of incident AAA (HR: 1.44; 95% CI: 1.02, 2.03; <italic>P</italic> = 0.040) (<xref ref-type="table" rid="T2"><bold>Table&#xa0;2</bold></xref>, <xref ref-type="supplementary-material" rid="SM1"><bold>Supplementary Figure&#xa0;4C</bold></xref>). Additionally, CCL20 expression was increased in human AAA tissues relative to normal abdominal aortic tissues (<xref ref-type="fig" rid="f4"><bold>Figure&#xa0;4N</bold></xref>, <xref ref-type="supplementary-material" rid="SM1"><bold>Supplementary Figure&#xa0;4B</bold></xref>). These findings suggest that CCL20 is primarily secreted by macrophages in AAA, with elevated levels in both tissues and blood, potentially implicating it in AAA progression.</p>
<table-wrap id="T1" position="float">
<label>Table&#xa0;1</label>
<caption>
<p>Demographic characteristics of participants from UK Biobank database.</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="middle" align="left">Characteristic</th>
<th valign="middle" align="left">Total population</th>
<th valign="middle" align="left">Participants without AAA</th>
<th valign="middle" align="left">Participants with AAA</th>
<th valign="middle" align="left"><italic>P</italic>-value</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="middle" align="left">N</td>
<td valign="middle" align="left">52,017</td>
<td valign="middle" align="left">51,688</td>
<td valign="middle" align="left">329</td>
<td valign="middle" align="left"/>
</tr>
<tr>
<td valign="middle" align="left">Age, years</td>
<td valign="middle" align="left">56.79 &#xb1; 8.21</td>
<td valign="middle" align="left">56.75 &#xb1; 8.21</td>
<td valign="middle" align="left">63.50 &#xb1; 5.49</td>
<td valign="middle" align="left">&lt;0.001</td>
</tr>
<tr>
<td valign="middle" align="left">Male, n (%)</td>
<td valign="middle" align="left">23965 (46.07)</td>
<td valign="middle" align="left">23690 (45.83)</td>
<td valign="middle" align="left">275 (83.59)</td>
<td valign="middle" align="left">&lt;0.001</td>
</tr>
<tr>
<td valign="middle" align="left">Ethnicity, n (%)</td>
<td valign="middle" align="left"/>
<td valign="middle" align="left"/>
<td valign="middle" align="left"/>
<td valign="middle" align="left">0.124</td>
</tr>
<tr>
<td valign="middle" align="left">&#x2003;White</td>
<td valign="middle" align="left">48524 (93.28)</td>
<td valign="middle" align="left">48205 (93.26)</td>
<td valign="middle" align="left">319 (96.96)</td>
<td valign="middle" align="left"/>
</tr>
<tr>
<td valign="middle" align="left">&#x2003;Mixed background</td>
<td valign="middle" align="left">343 (0.66)</td>
<td valign="middle" align="left">343 (0.66)</td>
<td valign="middle" align="left">0 (0.00)</td>
<td valign="middle" align="left"/>
</tr>
<tr>
<td valign="middle" align="left">&#x2003;South Asian</td>
<td valign="middle" align="left">959 (1.84)</td>
<td valign="middle" align="left">959 (1.86)</td>
<td valign="middle" align="left">0 (0.00)</td>
<td valign="middle" align="left"/>
</tr>
<tr>
<td valign="middle" align="left">&#x2003;Black</td>
<td valign="middle" align="left">1183 (2.27)</td>
<td valign="middle" align="left">1178 (2.28)</td>
<td valign="middle" align="left">5 (1.52)</td>
<td valign="middle" align="left"/>
</tr>
<tr>
<td valign="middle" align="left">&#x2003;Chinese</td>
<td valign="middle" align="left">145 (0.28)</td>
<td valign="middle" align="left">144 (0.28)</td>
<td valign="middle" align="left">1 (0.30)</td>
<td valign="middle" align="left"/>
</tr>
<tr>
<td valign="middle" align="left">&#x2003;Other</td>
<td valign="middle" align="left">608 (1.17)</td>
<td valign="middle" align="left">605 (1.17)</td>
<td valign="middle" align="left">3 (0.91)</td>
<td valign="middle" align="left"/>
</tr>
<tr>
<td valign="middle" align="left">&#x2003;Missing</td>
<td valign="middle" align="left">255 (0.49)</td>
<td valign="middle" align="left">254 (0.49)</td>
<td valign="middle" align="left">1 (0.30)</td>
<td valign="middle" align="left"/>
</tr>
<tr>
<td valign="middle" align="left">Educational level, n (%)</td>
<td valign="middle" align="left"/>
<td valign="middle" align="left"/>
<td valign="middle" align="left"/>
<td valign="middle" align="left">&lt;0.001</td>
</tr>
<tr>
<td valign="middle" align="left">&#x2003;No relevant qualifications</td>
<td valign="middle" align="left">16605 (31.92)</td>
<td valign="middle" align="left">16546 (32.01)</td>
<td valign="middle" align="left">59 (17.93)</td>
<td valign="middle" align="left"/>
</tr>
<tr>
<td valign="middle" align="left">&#x2003;CSEs or equivalent</td>
<td valign="middle" align="left">5691 (10.94)</td>
<td valign="middle" align="left">5668 (10.97)</td>
<td valign="middle" align="left">23 (6.99)</td>
<td valign="middle" align="left"/>
</tr>
<tr>
<td valign="middle" align="left">&#x2003;O levels, GCSEs, or equivalent</td>
<td valign="middle" align="left">10735 (20.64)</td>
<td valign="middle" align="left">10666 (20.64)</td>
<td valign="middle" align="left">69 (20.97)</td>
<td valign="middle" align="left"/>
</tr>
<tr>
<td valign="middle" align="left">&#x2003;A level, AS levels, or equivalent</td>
<td valign="middle" align="left">2773 (5.33)</td>
<td valign="middle" align="left">2761 (5.34)</td>
<td valign="middle" align="left">12 (3.65)</td>
<td valign="middle" align="left"/>
</tr>
<tr>
<td valign="middle" align="left">&#x2003;College or university degree</td>
<td valign="middle" align="left">6174 (11.87)</td>
<td valign="middle" align="left">6111 (11.82)</td>
<td valign="middle" align="left">63 (19.15)</td>
<td valign="middle" align="left"/>
</tr>
<tr>
<td valign="middle" align="left">&#x2003;Others</td>
<td valign="middle" align="left">9155 (17.60)</td>
<td valign="middle" align="left">9055 (17.52)</td>
<td valign="middle" align="left">100 (30.40)</td>
<td valign="middle" align="left"/>
</tr>
<tr>
<td valign="middle" align="left">&#x2003;Missing</td>
<td valign="middle" align="left">884 (1.70)</td>
<td valign="middle" align="left">881 (1.70)</td>
<td valign="middle" align="left">3 (0.91)</td>
<td valign="middle" align="left"/>
</tr>
<tr>
<td valign="middle" align="left">Townsend deprivation index, n (%)</td>
<td valign="middle" align="left"/>
<td valign="middle" align="left"/>
<td valign="middle" align="left"/>
<td valign="middle" align="left">0.711</td>
</tr>
<tr>
<td valign="middle" align="left">&#x2003;Q1</td>
<td valign="middle" align="left">10288 (19.78)</td>
<td valign="middle" align="left">10224 (19.80)</td>
<td valign="middle" align="left">64 (19.45)</td>
<td valign="middle" align="left"/>
</tr>
<tr>
<td valign="middle" align="left">&#x2003;Q2</td>
<td valign="middle" align="left">10233 (19.67)</td>
<td valign="middle" align="left">10169 (19.70)</td>
<td valign="middle" align="left">64 (19.45)</td>
<td valign="middle" align="left"/>
</tr>
<tr>
<td valign="middle" align="left">&#x2003;Q3</td>
<td valign="middle" align="left">9841 (18.92)</td>
<td valign="middle" align="left">9774 (18.93)</td>
<td valign="middle" align="left">67 (20.36)</td>
<td valign="middle" align="left"/>
</tr>
<tr>
<td valign="middle" align="left">&#x2003;Q4</td>
<td valign="middle" align="left">10568 (20.32)</td>
<td valign="middle" align="left">10510 (20.36)</td>
<td valign="middle" align="left">58 (17.63)</td>
<td valign="middle" align="left"/>
</tr>
<tr>
<td valign="middle" align="left">&#x2003;Q5</td>
<td valign="middle" align="left">11024 (21.19)</td>
<td valign="middle" align="left">10948 (21.21)</td>
<td valign="middle" align="left">76 (23.10)</td>
<td valign="middle" align="left"/>
</tr>
<tr>
<td valign="middle" align="left">&#x2003;Missing</td>
<td valign="middle" align="left">63 (0.12)</td>
<td valign="middle" align="left"/>
<td valign="middle" align="left"/>
<td valign="middle" align="left"/>
</tr>
<tr>
<td valign="middle" align="left">Body mass index, n (%)</td>
<td valign="middle" align="left"/>
<td valign="middle" align="left"/>
<td valign="middle" align="left"/>
<td valign="middle" align="left">&lt;0.001</td>
</tr>
<tr>
<td valign="middle" align="left">&#x2003; kg/m<sup>2</sup></td>
<td valign="middle" align="left">268 (0.52)</td>
<td valign="middle" align="left">267 (0.52)</td>
<td valign="middle" align="left">1 (0.30)</td>
<td valign="middle" align="left"/>
</tr>
<tr>
<td valign="middle" align="left">&#x2003;18.5 to &lt;25 kg/m<sup>2</sup></td>
<td valign="middle" align="left">16549 (31.81)</td>
<td valign="middle" align="left">16479 (32.04)</td>
<td valign="middle" align="left">70 (21.28)</td>
<td valign="middle" align="left"/>
</tr>
<tr>
<td valign="middle" align="left">&#x2003;25 to &lt;30 kg/m<sup>2</sup></td>
<td valign="middle" align="left">22222 (42.72)</td>
<td valign="middle" align="left">22068 (42.91)</td>
<td valign="middle" align="left">154 (46.81)</td>
<td valign="middle" align="left"/>
</tr>
<tr>
<td valign="middle" align="left">&#x2003;&#x2265;30 kg/m<sup>2</sup></td>
<td valign="middle" align="left">12724 (24.46)</td>
<td valign="middle" align="left">12620 (24.54)</td>
<td valign="middle" align="left">104 (31.61)</td>
<td valign="middle" align="left"/>
</tr>
<tr>
<td valign="middle" align="left">&#x2003;Missing</td>
<td valign="middle" align="left">254 (0.49)</td>
<td valign="middle" align="left"/>
<td valign="middle" align="left"/>
<td valign="middle" align="left"/>
</tr>
<tr>
<td valign="middle" align="left">Smoking status, n (%)</td>
<td valign="middle" align="left"/>
<td valign="middle" align="left"/>
<td valign="middle" align="left"/>
<td valign="middle" align="left">&lt;0.001</td>
</tr>
<tr>
<td valign="middle" align="left">&#x2003;Never</td>
<td valign="middle" align="left">28163 (54.14)</td>
<td valign="middle" align="left">28102 (54.37)</td>
<td valign="middle" align="left">61 (18.54)</td>
<td valign="middle" align="left"/>
</tr>
<tr>
<td valign="middle" align="left">&#x2003;Past</td>
<td valign="middle" align="left">18121 (34.84)</td>
<td valign="middle" align="left">17966 (34.76)</td>
<td valign="middle" align="left">155 (47.11)</td>
<td valign="middle" align="left"/>
</tr>
<tr>
<td valign="middle" align="left">&#x2003;Current</td>
<td valign="middle" align="left">5479 (10.53)</td>
<td valign="middle" align="left">5367 (10.38)</td>
<td valign="middle" align="left">112 (34.04)</td>
<td valign="middle" align="left"/>
</tr>
<tr>
<td valign="middle" align="left">Missing</td>
<td valign="middle" align="left">254 (0.49)</td>
<td valign="middle" align="left">253 (0.49)</td>
<td valign="middle" align="left">1 (0.30)</td>
<td valign="middle" align="left"/>
</tr>
<tr>
<td valign="middle" align="left">Alcohol drinking, n (%)</td>
<td valign="middle" align="left"/>
<td valign="middle" align="left"/>
<td valign="middle" align="left"/>
<td valign="middle" align="left">0.997</td>
</tr>
<tr>
<td valign="middle" align="left">&#x2003;Never</td>
<td valign="middle" align="left">2456 (4.72)</td>
<td valign="middle" align="left">2441 (4.72)</td>
<td valign="middle" align="left">15 (4.56)</td>
<td valign="middle" align="left"/>
</tr>
<tr>
<td valign="middle" align="left">&#x2003;Past</td>
<td valign="middle" align="left">2019 (3.88)</td>
<td valign="middle" align="left">2006 (3.88)</td>
<td valign="middle" align="left">13 (3.95)</td>
<td valign="middle" align="left"/>
</tr>
<tr>
<td valign="middle" align="left">&#x2003;Current</td>
<td valign="middle" align="left">47406 (91.14)</td>
<td valign="middle" align="left">47106 (91.14)</td>
<td valign="middle" align="left">300 (91.19)</td>
<td valign="middle" align="left"/>
</tr>
<tr>
<td valign="middle" align="left">&#x2003;Missing</td>
<td valign="middle" align="left">136 (0.26)</td>
<td valign="middle" align="left">135 (0.26)</td>
<td valign="middle" align="left">1 (0.30)</td>
<td valign="middle" align="left"/>
</tr>
<tr>
<td valign="middle" align="left">Leisure time physical activity, n (%)</td>
<td valign="middle" align="left"/>
<td valign="middle" align="left"/>
<td valign="middle" align="left"/>
<td valign="middle" align="left">0.037</td>
</tr>
<tr>
<td valign="middle" align="left">&#x2003; MET/min/weeks</td>
<td valign="middle" align="left">18200 (34.99)</td>
<td valign="middle" align="left">18096 (35.01)</td>
<td valign="middle" align="left">104 (31.61)</td>
<td valign="middle" align="left"/>
</tr>
<tr>
<td valign="middle" align="left">&#x2003;500 to &lt;1000 MET/min/weeks</td>
<td valign="middle" align="left">10689 (20.55)</td>
<td valign="middle" align="left">10630 (20.57)</td>
<td valign="middle" align="left">59 (17.93)</td>
<td valign="middle" align="left"/>
</tr>
<tr>
<td valign="middle" align="left">&#x2003;&#x2265;1000 MET/min/weeks</td>
<td valign="middle" align="left">18424 (35.42)</td>
<td valign="middle" align="left">18301 (35.41)</td>
<td valign="middle" align="left">123 (37.39)</td>
<td valign="middle" align="left"/>
</tr>
<tr>
<td valign="middle" align="left">&#x2003;Missing</td>
<td valign="middle" align="left">4704 (9.04)</td>
<td valign="middle" align="left">4661 (9.02)</td>
<td valign="middle" align="left">43 (13.07)</td>
<td valign="middle" align="left"/>
</tr>
<tr>
<td valign="middle" align="left">Healthy dietary, n (%)</td>
<td valign="middle" align="left">2356 (4.53)</td>
<td valign="middle" align="left">2342 (4.53)</td>
<td valign="middle" align="left">14 (4.26)</td>
<td valign="middle" align="left">0.884</td>
</tr>
<tr>
<td valign="middle" align="left">&#x2003;Missing</td>
<td valign="middle" align="left">1971 (3.79)</td>
<td valign="middle" align="left">1960 (3.79)</td>
<td valign="middle" align="left">11 (3.34)</td>
<td valign="middle" align="left"/>
</tr>
<tr>
<td valign="middle" align="left">Diabetes, n (%)</td>
<td valign="middle" align="left">2950 (5.67)</td>
<td valign="middle" align="left">2920 (5.65)</td>
<td valign="middle" align="left">30 (9.12)</td>
<td valign="middle" align="left">0.024</td>
</tr>
<tr>
<td valign="middle" align="left">&#x2003;Missing</td>
<td valign="middle" align="left">227 (0.44)</td>
<td valign="middle" align="left">226 (0.44)</td>
<td valign="middle" align="left">1 (0.30)</td>
<td valign="middle" align="left"/>
</tr>
<tr>
<td valign="middle" align="left">Hypertension, n (%)</td>
<td valign="middle" align="left">14592 (28.05)</td>
<td valign="middle" align="left">14429 (27.92)</td>
<td valign="middle" align="left">163 (49.54)</td>
<td valign="middle" align="left">&lt;0.001</td>
</tr>
<tr>
<td valign="middle" align="left">&#x2003;Missing</td>
<td valign="middle" align="left">61 (0.12)</td>
<td valign="middle" align="left">61 (0.12)</td>
<td valign="middle" align="left">0 (0.00)</td>
<td valign="middle" align="left"/>
</tr>
<tr>
<td valign="middle" align="left">Hyperlipidemia, n (%)</td>
<td valign="middle" align="left">6710 (12.90)</td>
<td valign="middle" align="left">6587 (12.74)</td>
<td valign="middle" align="left">123 (37.39)</td>
<td valign="middle" align="left">&lt;0.001</td>
</tr>
</tbody>
</table>
</table-wrap>
<table-wrap id="T2" position="float">
<label>Table&#xa0;2</label>
<caption>
<p>High circulating CCL20 level predicted higher risk of AAA.</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="middle" colspan="5" align="left">Associations between baseline circulating level and risk of AAA.</th>
</tr>
<tr>
<th valign="middle" align="left">Variable</th>
<th valign="middle" align="left">Crude HR (95% CI)</th>
<th valign="middle" align="left"><italic>P</italic>-value</th>
<th valign="middle" align="left">Adjusted HR (95% CI) *</th>
<th valign="middle" align="left"><italic>P</italic>-value</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="middle" align="left">CCL20, per 1-SD increase</td>
<td valign="middle" align="left">1.26 (1.15, 1.37)</td>
<td valign="middle" align="left">&lt;0.001</td>
<td valign="middle" align="left">1.11 (1.00, 1.23)</td>
<td valign="middle" align="left">0.047</td>
</tr>
<tr>
<td valign="middle" align="left">CCL20, quartiles</td>
<td valign="middle" align="left"/>
<td valign="middle" align="left"/>
<td valign="middle" align="left"/>
<td valign="middle" align="left"/>
</tr>
<tr>
<td valign="middle" align="left">Q1</td>
<td valign="middle" align="left">1.0</td>
<td valign="middle" align="left"/>
<td valign="middle" align="left">1.0</td>
<td valign="middle" align="left"/>
</tr>
<tr>
<td valign="middle" align="left">Q2</td>
<td valign="middle" align="left">1.30 (0.90, 1.89)</td>
<td valign="middle" align="left">0.167</td>
<td valign="middle" align="left">1.05 (0.72, 1.53)</td>
<td valign="middle" align="left">0.803</td>
</tr>
<tr>
<td valign="middle" align="left">Q3</td>
<td valign="middle" align="left">2.13 (1.51, 2.99</td>
<td valign="middle" align="left">&lt;0.001</td>
<td valign="middle" align="left">1.43 (1.01, 2.02)</td>
<td valign="middle" align="left">0.044</td>
</tr>
<tr>
<td valign="middle" align="left">Q4</td>
<td valign="middle" align="left">2.47 (1.77, 3.45)</td>
<td valign="middle" align="left">&lt;0.001</td>
<td valign="middle" align="left">1.44 (1.02, 2.03)</td>
<td valign="middle" align="left">0.040</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>*Adjusted for age, sex, ethnicity, educational attainment, socioeconomic deprivation, body mass index, smoking status, alcohol drinking, healthy diet, leisure time physical activity, diabetes, hypertension, and hypercholesterolemia.</p></fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="s3_5">
<label>3.5</label>
<title>Macrophages recruited significant numbers of immune cells through the CCL20-CCR6 axis</title>
<p>As CCR6 is the sole receptor for CCL20 (<xref ref-type="bibr" rid="B33">33</xref>, <xref ref-type="bibr" rid="B36">36</xref>, <xref ref-type="bibr" rid="B37">37</xref>), we visualized its interaction relationship with CCL20 in the Cytokine-cytokine receptor interaction pathway (<xref ref-type="supplementary-material" rid="SM1"><bold>Supplementary Figure&#xa0;4D</bold></xref>). Single-cell datasets showed that CCR6 was mainly expressed in T cells and B cells (<xref ref-type="fig" rid="f5"><bold>Figure&#xa0;5A</bold></xref>), a finding confirmed by IF co-localization in human AAA tissues (<xref ref-type="fig" rid="f5"><bold>Figures&#xa0;5B, C</bold></xref>). Comparative analysis revealed significantly elevated CCR6 expression in T cells and B cells from AAA tissues (<xref ref-type="fig" rid="f5"><bold>Figure&#xa0;5D</bold></xref>). Western blot and IF analyses further demonstrated higher CCR6 expression in human AAA tissues (<xref ref-type="fig" rid="f5"><bold>Figures&#xa0;5E&#x2013;G</bold></xref>; <xref ref-type="supplementary-material" rid="SM1"><bold>Supplementary Figures&#xa0;5A, B</bold></xref>). Consistently, CCR6 mRNA levels were upregulated in bulk RNA-seq datasets (<xref ref-type="fig" rid="f5"><bold>Figure&#xa0;5H</bold></xref>). Thus, CCR6 expression was elevated in AAA tissues, primarily in T cells and B cells.</p>
<fig id="f5" position="float">
<label>Figure&#xa0;5</label>
<caption>
<p>Macrophages Recruit Significant Numbers of Immune Cells through the CCL20-CCR6 Axis. <bold>(A)</bold> CCR6 expression in 11 cell types in GSE166676 and GSE226492. <bold>(B)</bold> Representative images of IF co-localization of CCR6 (green) and B cells (CD19, red). Nuclei were stained with DAPI (blue), scale bar, 50&#x3bc;m. <bold>(C)</bold> Representative images of IF co-localization of CCR6 (green) and T cells (CD3, yellow). Nuclei were stained with DAPI (blue), scale bar, 50&#x3bc;m. The synchronized fluctuations of CCR6 (green)and T cells (CD3, yellow) curves indicated co-localization at these discrete sites. <bold>(D)</bold> CCR6 expression in 11 cell types. <bold>(E)</bold> CCR6 protein expression in human tissues between the normal group and the AAA group. <bold>(F, G)</bold> Representative images of IF of CCR6 (green) expression in the the normal (n=5) and AAA group (n=6). Nuclei were stained with DAPI (blue), scale bar, 50 &#x3bc;m. <bold>(H)</bold> CCR6 mRNA expression in GSE269845 and GSE183464. <bold>(I)</bold> Cell Chat between macrophages and other cells in the CCL pathway signaling. <bold>(J)</bold> Representative images of IF of Macrophages (CD68, green), B cells (CD19, red), T cells (CD3, yellow) in the normal and AAA groups. Nuclei were stained with DAPI (blue), scale bar, 50 &#x3bc;m. <bold>(K)</bold> Flow cytometry of CD19 cells frequency in the LPS (100ng/ml) group and the LPS + CCL20 Antibody group <bold>(L)</bold> Flow cytometry of CD3 cells frequency in LPS (100ng/ml) group and the LPS + CCL20 Antibody group, *<italic>P</italic> &lt; 0.05, **<italic>P</italic> &lt; 0.01, ***<italic>P</italic> &lt; 0.001.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-17-1780720-g005.tif">
<alt-text content-type="machine-generated">Panel A presents a dot plot illustrating CCR6 gene expression across various cell types, while panels B and C show immunofluorescence images with color-coded markers and intensity profiles in AAA tissue. Panel D displays summarized CCR6 expression by cell type in normal and AAA samples, and panel E presents a western blot comparing CCR6 protein levels in normal versus AAA tissue. Panels F and G provide immunofluorescence images in normal and AAA tissues, respectively. Panel H contains violin plots for CCR6 transcript abundance in two cohorts. Panel I features a dot plot of cell-cell pathway signaling probabilities, and panel J overlays fluorescence micrographs of immune marker co-localization in normal and AAA samples. Panels K and L present flow cytometry dot plots with quantified bar graphs assessing immune cell frequencies following LPS and LPS plus anti-CCL20 treatments.</alt-text>
</graphic></fig>
<p>To explore potential chemokine-mediated communication involving macrophages during AAA, we performed CellChat analysis focusing on the CCL chemokine family. This analysis suggested enriched CCL-related communication patterns between macrophages and multiple immune cell types in AAA samples. In particular, inferred CCL20-CCR6-associated communication between macrophages and T cells, B cells, and NKT cells was predominantly observed in AAA tissues (<xref ref-type="fig" rid="f5"><bold>Figure&#xa0;5I</bold></xref>). Consistent with the cellular composition revealed by single-cell datasets (<xref ref-type="fig" rid="f1"><bold>Figures&#xa0;1C, D</bold></xref>), immunofluorescence analysis of human tissues showed no significant difference in macrophage abundance between groups, but demonstrated increased infiltration of adaptive immune cells, including T cells and B cells, in AAA tissues (<xref ref-type="fig" rid="f5"><bold>Figure&#xa0;5J</bold></xref>). These observations, together with the inferred communication patterns, suggested a potential role for macrophage-derived CCL20-CCR6 signaling in immune cell recruitment within AAA lesions. To functionally test this hypothesis, we performed Transwell co-culture experiments using LPS-stimulated macrophages and T or B cells in the presence of a CCL20-neutralizing antibody (10 ng/ml). Flow cytometric analysis showed that blockade of the CCL20-CCR6 axis significantly reduced the migration of both T cells and B cells (<xref ref-type="fig" rid="f5"><bold>Figures&#xa0;5K, L</bold></xref>). Collectively, these functional data support a role for macrophage-derived CCL20-CCR6 signaling in promoting immune cell migration, providing experimental validation for the communication patterns suggested by CellChat analysis.</p>
</sec>
<sec id="s3_6">
<label>3.6</label>
<title>Targeting the CCL20-CCR6 axis inhibited AAA progression</title>
<p>To validate the role of the CCL20-CCR6 axis in AAA development, we established an AAA model in <italic>ApoE</italic><sup>&#x2013;/&#x2013;</sup> mice through Ang-II infusion (1,000 ng/kg/min). Interventions were administered via tail vein injections of a specific knockdown of AAV-shCCL20/AAV-shCCR6 (<xref ref-type="fig" rid="f6"><bold>Figure&#xa0;6A</bold></xref>).</p>
<fig id="f6" position="float">
<label>Figure&#xa0;6</label>
<caption>
<p>Targeting the CCL20-CCR6 Axis Suppresses AAA Progression. <bold>(A)</bold> Schematic representation of study design, n=15 per group. <bold>(B)</bold> RT-qPCR of knockdown efficiencies for CCL20 and CCR6. <bold>(C)</bold> The AAA incidence. <bold>(D)</bold> The maximal external aortic diameter (mm). <bold>(E)</bold> Representative images of morphology of the whole aorta of all groups. <bold>(F)</bold> Representative vascular Doppler ultrasound images of the aorta of all groups. (N&#x2009;=&#x2009;15). <bold>(G)</bold> Representative hematoxylin and eosin (HE), Elastica van Gieson (EVG), and elastin degradation grading, Masson trichrome staining. <bold>(H)</bold> Representative IF images of CCR6 (green), T cells (CD3, yellow), and B cells (CD19, red) in the aorta tissues of all groups. Nuclei were stained with DAPI (blue), scale bar, 20 &#x3bc;m. *<italic>P</italic> &lt; 0.05, **<italic>P</italic> &lt; 0.01, ***<italic>P</italic> &lt; 0.001, and ****<italic>P</italic> &lt; 0.0001.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-17-1780720-g006.tif">
<alt-text content-type="machine-generated">Scientific figure composed of multiple panels displaying an experimental workflow in mice for abdominal aortic aneurysm, including summary diagrams, bar graphs with significance asterisks, dissected aortas, ultrasound images with red arrows highlighting abnormalities, histological stains (HE, EVG, Masson) with graded elastin degradation, and immunofluorescence images for CCR6, CD3, and CD19 with DAPI counterstain, comparing control and experimental groups including gene knockdowns.</alt-text>
</graphic></fig>
<p>Specifically, RT-qPCR validated the knockdown efficiencies of CCL20 and CCR6 in aortic tissues. Expression levels of both CCL20 and CCR6 were significantly higher in the AAA group compared to controls (<xref ref-type="fig" rid="f6"><bold>Figure&#xa0;6B</bold></xref>). Knockdown of CCL20 or CCR6 markedly reduced AAA incidence (<xref ref-type="fig" rid="f6"><bold>Figure&#xa0;6C</bold></xref>). These findings were further corroborated by vascular Doppler ultrasound imaging and measurements of maximal external aortic diameter (<xref ref-type="fig" rid="f6"><bold>Figures&#xa0;6D&#x2013;F</bold></xref>). Morphological and histological analyses demonstrated that disrupting the CCL20-CCR6 axis attenuated inflammation, elastin degradation, and collagen deposition in the aortic wall (<xref ref-type="fig" rid="f6"><bold>Figure&#xa0;6G</bold></xref>). Additionally, IF and IHC staining revealed elevated CCR6 expression alongside abundant infiltration of T cells and B cells in AAA tissues (<xref ref-type="supplementary-material" rid="SM1"><bold>Supplementary Figures&#xa0;5C, D</bold></xref>). In contrast, knockdown of CCL20 or CCR6 diminished the accumulation of these immune cells (<xref ref-type="fig" rid="f6"><bold>Figure&#xa0;6H</bold></xref>). By using F4/80<sup>+</sup>CD86<sup>+</sup>iNOS<sup>+</sup> as representative M1-like markers and F4/80<sup>+</sup>CD206<sup>+</sup>Arg1<sup>+</sup> as representative M2-like markers in multiplex immunofluorescence, we further validated the macrophage polarization status. The experimental results indicate that blockade the CCL20-CCR6 axis weakened the pro-inflammatory M1 polarization tendency and enhanced the anti-inflammatory M2 polarization tendency (<xref ref-type="supplementary-material" rid="SM1"><bold>Supplementary Figure&#xa0;6</bold></xref>). Collectively, these results indicate that targeting the CCL20-CCR6 axis reduces T cell and B cell infiltration and suppresses AAA progression.</p>
</sec>
</sec>
<sec id="s4" sec-type="discussion">
<label>4</label>
<title>Discussion</title>
<p>This study employed integrated single-cell and bulk RNA sequencing, alongside experimental and external data validations, to elucidate the cellular and molecular underpinnings of AAA pathogenesis. Our analyses revealed profound immune cell infiltration (particularly T cells and B cells) and structural cell depletion (fibroblasts, endothelial cells, and SMCs) in AAA tissues, driven by imbalanced macrophage polarization favoring pro-inflammatory M1-like macrophages. This imbalance promoted CCL20 secretion, which recruits CCR6-expressing immune cells (CCR6+ T cells and CCR6+ B cells) into the aneurysmal tissue. ELISA and IF analyses confirmed significantly elevated CCL20 levels in serum and tissue samples from AAA patients. Using a knockdown model of the CCL20-CCR6 axis in AAA and an <italic>in vitro</italic> neutralization model of CCL20-mediated macrophage chemotaxis, we evaluated the axis&#x2019;s impact on AAA. Our findings highlight the CCL20-CCR6 axis as a key regulator of AAA pathogenesis (<xref ref-type="fig" rid="f7"><bold>Figure&#xa0;7</bold></xref>) and a potential therapeutic target.</p>
<fig id="f7" position="float">
<label>Figure&#xa0;7</label>
<caption>
<p>The role of CCL20-CCR6 axis in AAA formation. Macrophage polarization was imbalanced, with enriched M1-like macrophages and elevated CCL20 secretion. CCL20 promoted the recruitment of CCR6+ immune cells (T and B cells) and AAA formation.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-17-1780720-g007.tif">
<alt-text content-type="machine-generated">Medical illustration of an abdominal aortic aneurysm shows immune cell infiltration within the vessel wall, including M1 and M2 macrophages, B cells, T cells, CCL20, and CCR6, with a labeled legend.</alt-text>
</graphic></fig>
<p>Macrophage infiltration and polarization evolve throughout aneurysm development (<xref ref-type="bibr" rid="B8">8</xref>). We note that M1/M2-like macrophage signatures represent simplified polarization axes and do not capture the full spectrum of macrophage heterogeneity; therefore, these results should be interpreted as functional tendencies rather than discrete macrophage subtypes. Additionally, cytokine-cytokine receptor interaction pathways were highly activated in AAA macrophages. Our results showed no significant difference in macrophage proportions between the AAA and normal groups with the imbalance between M1-like and M2-like macrophage polarization. Macrophage polarization is a critical driver of AAA (<xref ref-type="bibr" rid="B56">56</xref>&#x2013;<xref ref-type="bibr" rid="B59">59</xref>). Pro-inflammatory M1 macrophages accelerate AAA by exacerbating inflammation and secreting cytokines (<xref ref-type="bibr" rid="B22">22</xref>, <xref ref-type="bibr" rid="B60">60</xref>, <xref ref-type="bibr" rid="B61">61</xref>). In our study, M1-like macrophage polarization and altered gene expression profiles were evident in AAA macrophages, with an imbalance favoring M1-like over M2-like. IL-1&#x3b1;, CXCL10, and CCL20 emerged as the top three secreted chemokines, with IL-1&#x3b1; and CXCL10 previously implicated in AAA pathogenesis (<xref ref-type="bibr" rid="B62">62</xref>, <xref ref-type="bibr" rid="B63">63</xref>). This study focuses on the third key chemokine, CCL20, and its exclusive receptor, CCR6, to delineate their specific roles in shaping the AAA immune microenvironment and driving AAA progression (<xref ref-type="bibr" rid="B64">64</xref>). The CCL20-CCR6 axis regulates immune responses in cardiovascular diseases (<xref ref-type="bibr" rid="B37">37</xref>), but its role in AAA remains underexplored. We observed that M1-like macrophage polarization significantly increased CCL20 expression in AAA serum and tissues. Consistent with the previous study (<xref ref-type="bibr" rid="B55">55</xref>), CCL20 serves as a potential AAA biomarker in large cohorts based on our and UK Biobank data. Due to challenges in obtaining normal aortic tissue, the sample size for the normal group (n=5) was relatively small. However, our study has demonstrated the pivotal role of the CCL20-CCR6 axis in AAA. Future research with larger sample sizes will be essential.</p>
<p>Immune cell infiltration has long been recognized as a fundamental mechanism in the chronic inflammatory progression of AAA, with chemokines playing a pivotal role (<xref ref-type="bibr" rid="B20">20</xref>, <xref ref-type="bibr" rid="B65">65</xref>, <xref ref-type="bibr" rid="B66">66</xref>). Consistent with previous findings (<xref ref-type="bibr" rid="B67">67</xref>), our single-cell analysis revealed a profound cellular imbalance in AAA tissues, characterized by extensive immune cell infiltration (T cells and B cells) and loss of structural cells (fibroblasts, endothelial cells, and SMCs). Ro/e analysis further demonstrated that immune cells (T cells and B cells) exhibited a significant tissue preference towards AAA tissues, suggesting a strong association with aneurysm progression risk. Given the limited donor number, Ro/e analysis was used as a descriptive tool to summarize cell-type distribution trends, and future studies with larger cohorts will be required for robust donor-level inference. CellChat analysis indicated macrophages emerged as particularly prominent in communication with T cells, B cells, and NKT cells in AAA group. CellChat-based communication analyses are inferential and hypothesis-generating, and future donor-aware modeling and functional validation will be required to further define the biological relevance of these signaling pathways.</p>
<p>We propose that the active CCL20-CCR6 axis provide a mechanistic framework to explain this specific recruitment of CCR6-expressing immune cells (CCR6+ T cells and CCR6+ B cells) and the ensuing inflammatory cascade. T cells represent the dominant immune cell population in AAA (<xref ref-type="bibr" rid="B25">25</xref>), where they can promote AAA formation and stimulate macrophages to produce pro-inflammatory mediators in AAA models like Interleukin-17 (IL-17) and TNF-&#x3b1; (<xref ref-type="bibr" rid="B15">15</xref>, <xref ref-type="bibr" rid="B68">68</xref>, <xref ref-type="bibr" rid="B69">69</xref>). IL-17 can stimulate SMCs and&#xa0;fibroblasts to secrete matrix metalloproteinases and pro-inflammatory cytokines including CCL20, thereby establishing a positive feedback loop that sustains continuous lymphocyte recruitment (<xref ref-type="bibr" rid="B70">70</xref>, <xref ref-type="bibr" rid="B71">71</xref>). Furthermore, cytokines from other T cell subsets, such as Interferon-gamma (IFN-&#x3b3;) from Th1 cells, can&#xa0;contribute to orchestrate extracellular matrix remodeling (<xref ref-type="bibr" rid="B68">68</xref>). Concurrently, infiltrating B cells influence AAA progression by secreting immunoglobulins (e.g., Immunoglobulin A&amp;Immunoglobulin G) and cytokines like IL-6 and TNF-&#x3b1;, which degrade the aortic wall&#xa0;and exacerbate inflammatory responses (<xref ref-type="bibr" rid="B16">16</xref>). Depleting B cells protects mice from experimental AAA and fosters an immunosuppressive aortic environment (<xref ref-type="bibr" rid="B30">30</xref>). The CCL20-CCR6 axis links macrophage activation to the targeted recruitment of&#xa0;CCR6+ T cells and CCR6+ B cells. The secretory products of&#xa0;these effector cells act back on vascular wall cells and immune cells, aggravating the inflammatory response and accelerating aneurysm progression.</p>
<p>Inhibiting chemokine axes has proven effective in AAA animal models, such as CCL5-CCR5 or CCL2-CCR2 pathways (<xref ref-type="bibr" rid="B72">72</xref>&#x2013;<xref ref-type="bibr" rid="B74">74</xref>). The CCL20-CCR6 axis is vital in regulating immune responses during chronic inflammation in AAA, underscoring the need to develop therapeutic strategies targeting the axis. Overexpressed CCL20 promotes aortic elastin degradation, inhibits M2 polarization, and accelerates AAA (<xref ref-type="bibr" rid="B34">34</xref>), suggesting it exacerbates inflammation and drives progression. In atherosclerosis, the deletion of CCR6 effectively ameliorates inflammatory progression and plaque size (<xref ref-type="bibr" rid="B41">41</xref>, <xref ref-type="bibr" rid="B75">75</xref>). However, the mechanisms and efficacy of targeting CCL20-CCR6 in AAA are unclear. Our study provides initial evidence that blockade of this axis reduces aortic diameter, aneurysm incidence, and immune cells infiltration in AngII-induced ApoE<sup>&#x2013;/&#x2013;</sup> male mice AAA model under a high-fat diet, potential gender bias in the effects should be considered. Consistent with prior studies, our AAA model successfully recapitulates the key pathological features of human AAA, including chronic inflammation and macrophage-dominated immune infiltration (<xref ref-type="bibr" rid="B11">11</xref>, <xref ref-type="bibr" rid="B76">76</xref>). Although there are potential differences in the specific immune cell subset proportions and the disease timeline from AAA in human, the model has been used to explore the role of CCL20-CCR6 axis in AAA-related vascular lesions and immune features (<xref ref-type="bibr" rid="B34">34</xref>).</p>
<p>This study integrates bioinformatics analysis with experimental validation to explore the cellular and molecular mechanisms underlying AAA pathogenesis. Our analysis reveals a key role of CCL20 secretion, driven by an imbalance in M1-like macrophages polarization, which recruits CCR6+ immune cells (such as CCR6+ T cells and CCR6+ B cells) to promote AAA development. Our experimental framework already integrates two levels of evidence: 1) Genetic Evidence <italic>in vivo</italic> (AAV-shCCL20 knockdown) demonstrating the necessity of CCL20 in disease progression within the complex tissue microenvironment; 2) Pharmacological Evidence <italic>in vitro</italic> (CCL20-neutralizing antibody) confirming the functional consequence of blockade the CCL20-CCR6 axis. While our genetic intervention lays a crucial mechanistic groundwork, future pharmacological validation using CCL20-neutralizing antibodies or receptor antagonists <italic>in vivo</italic> will be an essential next step toward clinical translation.</p>
</sec>
<sec id="s5" sec-type="conclusions">
<label>5</label>
<title>Conclusion</title>
<p>Macrophage-derived CCL20 recruited CCT6+ lymphocytes and promoted AAA progression. Inhibition of the CCL20-CCR6 axis reduced the recruitment of immune cells and relieved AAA progression. CCL20 may serve as a novel diagnostic biomarker and therapeutic target for AAA.</p>
</sec>
</body>
<back>
<sec id="s6" sec-type="data-availability">
<title>Data availability statement</title>
<p>The original contributions presented in the study are included in the article/<xref ref-type="supplementary-material" rid="SM1"><bold>Supplementary Material</bold></xref>. Further inquiries can be directed to the corresponding author/s.</p></sec>
<sec id="s7" sec-type="ethics-statement">
<title>Ethics statement</title>
<p>The studies involving humans were approved by the Ethics Committee of Qilu Hospital of Shandong University (Approval No.: KYLL-202503-09-046-1). The studies were conducted in accordance with the local legislation and institutional requirements. The human samples used in this study were acquired from Written informed consent was obtained from all participants or the organ donors&#x2019; families. Human AAA tissues were collected from six patients (4 males, 2 females; age range: 58-71 years, median: 67.5) undergoing open surgical repair, and normal aortic tissues from six organ donors (5 males, 1 female; age range: 16-74 years, median: 53.5) deceased from cerebral hemorrhage. Written informed consent for participation was not required from the participants or the participants&#x2019; legal guardians/next of kin in accordance with the national legislation and institutional requirements. The animal study was approved by the Experimental Animal Ethics Committee of Qilu Hospital of Shandong University (Approval No.: DWLL-2024-214). The study was conducted in accordance with the local legislation and institutional requirements.</p></sec>
<sec id="s8" sec-type="author-contributions">
<title>Author contributions</title>
<p>QR: Conceptualization, Investigation, Resources, Writing &#x2013; original draft, Writing &#x2013; review &amp; editing. TS: Data curation, Formal analysis, Methodology, Writing &#x2013; original draft, Writing &#x2013; review &amp; editing. SS: Funding acquisition, Investigation, Resources, Writing &#x2013; original draft, Writing &#x2013; review &amp; editing. YC: Investigation, Resources, Writing &#x2013; original draft. LW:&#xa0;Investigation, Resources, Writing &#x2013; original draft. YZ: Investigation, Resources, Writing &#x2013; original draft. FW:&#xa0;Investigation, Resources, Writing &#x2013; original draft. PS: Investigation, Resources, Writing &#x2013; original draft. KX:&#xa0;Investigation, Resources, Writing &#x2013; original draft. HB: Data curation, Formal analysis, Methodology, Writing &#x2013; original draft. DG: Formal analysis, Methodology, Writing&#xa0;&#x2013; original draft. QH: Data curation, Formal analysis, Methodology, Writing &#x2013; original draft. MZ: Data curation, Formal analysis, Writing &#x2013; original draft. JY: Project administration, Supervision, Validation, Writing &#x2013; original draft. JJ: Project administration, Supervision, Validation, Writing &#x2013; original draft. WZ: Conceptualization, Project administration, Supervision, Validation, Writing &#x2013; original draft, Writing &#x2013; review &amp; editing. XD: Conceptualization, Funding acquisition, Project administration, Supervision, Validation, Writing &#x2013; original draft, Writing &#x2013; review &amp; editing.</p></sec>
<ack>
<title>Acknowledgments</title>
<p>The authors thank Prof. Qiang Fen, Prof. Xiaopeng Qi, Dr. Lei Zheng, and Dr. Yanfeng Li from Shandong University for their valuable help and suggestions. We are grateful to Prof. Hui Zhang, Prof. Zeyang Liu, and Prof. Zhaogang Dong from Qilu Hospital of Shandong University for human sample collection. We also thank Dr. Tao Tang from the Department of Pathology, 971 Hospital of the Navy of the Chinese People&#x2032; s Liberation Army, for his invaluable assistance. We thank Medjaden Inc. for scientific editing of this manuscript.</p>
</ack>
<sec id="s10" sec-type="COI-statement">
<title>Conflict of interest</title>
<p>The authors declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec>
<sec id="s11" sec-type="ai-statement">
<title>Generative AI statement</title>
<p>The author(s) declared that generative AI was not used in the creation of this manuscript.</p>
<p>Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.</p></sec>
<sec id="s12" sec-type="disclaimer">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></sec>
<sec id="s13" sec-type="supplementary-material">
<title>Supplementary material</title>
<p>The Supplementary Material for this article can be found online at: <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fimmu.2026.1780720/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fimmu.2026.1780720/full#supplementary-material</ext-link></p>
<supplementary-material xlink:href="DataSheet1.zip" id="SM1" mimetype="application/zip"/>
<supplementary-material xlink:href="DataSheet2.pdf" id="SM2" mimetype="application/pdf"/></sec>
<ref-list>
<title>References</title>
<ref id="B1">
<label>1</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Liu</surname> <given-names>Y</given-names></name>
<name><surname>Wang</surname> <given-names>H</given-names></name>
<name><surname>Yu</surname> <given-names>M</given-names></name>
<name><surname>Cai</surname> <given-names>L</given-names></name>
<name><surname>Zhao</surname> <given-names>Y</given-names></name>
<name><surname>Cheng</surname> <given-names>Y</given-names></name>
<etal/>
</person-group>. 
<article-title>Hypertriglyceridemia as a key contributor to abdominal aortic aneurysm development and rupture: insights from genetic and experimental models</article-title>. <source>Circulation</source>. (<year>2025</year>) <volume>152</volume>:<page-range>862&#x2013;81</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1161/circulationaha.125.074737</pub-id>, PMID: <pub-id pub-id-type="pmid">40762097</pub-id>
</mixed-citation>
</ref>
<ref id="B2">
<label>2</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Nordon</surname> <given-names>IM</given-names></name>
<name><surname>Hinchliffe</surname> <given-names>RJ</given-names></name>
<name><surname>Loftus</surname> <given-names>IM</given-names></name>
<name><surname>Thompson</surname> <given-names>MM</given-names></name>
</person-group>. 
<article-title>Pathophysiology and epidemiology of abdominal aortic aneurysms</article-title>. <source>Nat Rev Cardiol</source>. (<year>2011</year>) <volume>8</volume>:<fpage>92</fpage>&#x2013;<lpage>102</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/nrcardio.2010.180</pub-id>, PMID: <pub-id pub-id-type="pmid">21079638</pub-id>
</mixed-citation>
</ref>
<ref id="B3">
<label>3</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Kontopodis</surname> <given-names>N</given-names></name>
<name><surname>Galanakis</surname> <given-names>N</given-names></name>
<name><surname>Antoniou</surname> <given-names>SA</given-names></name>
<name><surname>Tsetis</surname> <given-names>D</given-names></name>
<name><surname>Ioannou</surname> <given-names>CV</given-names></name>
<name><surname>Veith</surname> <given-names>FJ</given-names></name>
<etal/>
</person-group>. 
<article-title>Meta-analysis and meta-regression analysis of outcomes of endovascular and open repair for ruptured abdominal aortic aneurysm</article-title>. <source>Eur J Vasc Endovasc Surg</source>. (<year>2020</year>) <volume>59</volume>:<fpage>399</fpage>&#x2013;<lpage>410</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.ejvs.2019.12.023</pub-id>, PMID: <pub-id pub-id-type="pmid">31932143</pub-id>
</mixed-citation>
</ref>
<ref id="B4">
<label>4</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Sakalihasan</surname> <given-names>N</given-names></name>
<name><surname>Michel</surname> <given-names>JB</given-names></name>
<name><surname>Katsargyris</surname> <given-names>A</given-names></name>
<name><surname>Kuivaniemi</surname> <given-names>H</given-names></name>
<name><surname>Defraigne</surname> <given-names>JO</given-names></name>
<name><surname>Nchimi</surname> <given-names>A</given-names></name>
<etal/>
</person-group>. 
<article-title>Abdominal aortic aneurysms</article-title>. <source>Nat Rev Dis Primers</source>. (<year>2018</year>) <volume>4</volume>:<fpage>34</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41572-018-0030-7</pub-id>, PMID: <pub-id pub-id-type="pmid">30337540</pub-id>
</mixed-citation>
</ref>
<ref id="B5">
<label>5</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Filiberto</surname> <given-names>AC</given-names></name>
<name><surname>Spinosa</surname> <given-names>MD</given-names></name>
<name><surname>Elder</surname> <given-names>CT</given-names></name>
<name><surname>Su</surname> <given-names>G</given-names></name>
<name><surname>Leroy</surname> <given-names>V</given-names></name>
<name><surname>Ladd</surname> <given-names>Z</given-names></name>
<etal/>
</person-group>. 
<article-title>Endothelial pannexin-1 channels modulate macrophage and smooth muscle cell activation in abdominal aortic aneurysm formation</article-title>. <source>Nat Commun</source>. (<year>2022</year>) <volume>13</volume>:<fpage>1521</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41467-022-29233-4</pub-id>, PMID: <pub-id pub-id-type="pmid">35315432</pub-id>
</mixed-citation>
</ref>
<ref id="B6">
<label>6</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Anagnostakos</surname> <given-names>J</given-names></name>
<name><surname>Lal</surname> <given-names>BK</given-names></name>
</person-group>. 
<article-title>Abdominal aortic aneurysms</article-title>. <source>Prog Cardiovasc Dis</source>. (<year>2021</year>) <volume>65</volume>:<fpage>34</fpage>&#x2013;<lpage>43</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.pcad.2021.03.009</pub-id>, PMID: <pub-id pub-id-type="pmid">33831398</pub-id>
</mixed-citation>
</ref>
<ref id="B7">
<label>7</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Wang</surname> <given-names>SK</given-names></name>
<name><surname>Murphy</surname> <given-names>MP</given-names></name>
</person-group>. 
<article-title>Immune modulation as a treatment for abdominal aortic aneurysms</article-title>. <source>Circ Res</source>. (<year>2018</year>) <volume>122</volume>:<page-range>925&#x2013;7</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1161/circresaha.118.312870</pub-id>, PMID: <pub-id pub-id-type="pmid">29599276</pub-id>
</mixed-citation>
</ref>
<ref id="B8">
<label>8</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Raffort</surname> <given-names>J</given-names></name>
<name><surname>Lareyre</surname> <given-names>F</given-names></name>
<name><surname>Cl&#xe9;ment</surname> <given-names>M</given-names></name>
<name><surname>Hassen-Khodja</surname> <given-names>R</given-names></name>
<name><surname>Chinetti</surname> <given-names>G</given-names></name>
<name><surname>Mallat</surname> <given-names>Z</given-names></name>
</person-group>. 
<article-title>Monocytes and macrophages in abdominal aortic aneurysm</article-title>. <source>Nat Rev Cardiol</source>. (<year>2017</year>) <volume>14</volume>:<page-range>457&#x2013;71</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/nrcardio.2017.52</pub-id>, PMID: <pub-id pub-id-type="pmid">28406184</pub-id>
</mixed-citation>
</ref>
<ref id="B9">
<label>9</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Dunkelberger</surname> <given-names>JR</given-names></name>
<name><surname>Song</surname> <given-names>WC</given-names></name>
</person-group>. 
<article-title>Complement and its role in innate and adaptive immune responses</article-title>. <source>Cell Res</source>. (<year>2010</year>) <volume>20</volume>:<fpage>34</fpage>&#x2013;<lpage>50</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/cr.2009.139</pub-id>, PMID: <pub-id pub-id-type="pmid">20010915</pub-id>
</mixed-citation>
</ref>
<ref id="B10">
<label>10</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Adam</surname> <given-names>M</given-names></name>
<name><surname>Kooreman</surname> <given-names>NG</given-names></name>
<name><surname>Jagger</surname> <given-names>A</given-names></name>
<name><surname>Wagenh&#xe4;user</surname> <given-names>MU</given-names></name>
<name><surname>Mehrkens</surname> <given-names>D</given-names></name>
<name><surname>Wang</surname> <given-names>Y</given-names></name>
<etal/>
</person-group>. 
<article-title>Systemic upregulation of il-10 (Interleukin-10) using a nonimmunogenic vector reduces growth and rate of dissecting abdominal aortic aneurysm</article-title>. <source>Arterioscler Thromb Vasc Biol</source>. (<year>2018</year>) <volume>38</volume>:<page-range>1796&#x2013;805</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1161/atvbaha.117.310672</pub-id>, PMID: <pub-id pub-id-type="pmid">29880489</pub-id>
</mixed-citation>
</ref>
<ref id="B11">
<label>11</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Sawada</surname> <given-names>H</given-names></name>
<name><surname>Lu</surname> <given-names>HS</given-names></name>
<name><surname>Cassis</surname> <given-names>LA</given-names></name>
<name><surname>Daugherty</surname> <given-names>A</given-names></name>
</person-group>. 
<article-title>Twenty years of studying angii (Angiotensin ii)-induced abdominal aortic pathologies in mice: continuing questions and challenges to provide insight into the human disease</article-title>. <source>Arterioscler Thromb Vasc Biol</source>. (<year>2022</year>) <volume>42</volume>:<page-range>277&#x2013;88</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1161/atvbaha.121.317058</pub-id>, PMID: <pub-id pub-id-type="pmid">35045728</pub-id>
</mixed-citation>
</ref>
<ref id="B12">
<label>12</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Xiao</surname> <given-names>J</given-names></name>
<name><surname>Angsana</surname> <given-names>J</given-names></name>
<name><surname>Wen</surname> <given-names>J</given-names></name>
<name><surname>Smith</surname> <given-names>SV</given-names></name>
<name><surname>Park</surname> <given-names>PW</given-names></name>
<name><surname>Ford</surname> <given-names>ML</given-names></name>
<etal/>
</person-group>. 
<article-title>Syndecan-1 displays a protective role in aortic aneurysm formation by modulating T cell-mediated responses</article-title>. <source>Arterioscler Thromb Vasc Biol</source>. (<year>2012</year>) <volume>32</volume>:<page-range>386&#x2013;96</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1161/atvbaha.111.242198</pub-id>, PMID: <pub-id pub-id-type="pmid">22173227</pub-id>
</mixed-citation>
</ref>
<ref id="B13">
<label>13</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Dale</surname> <given-names>MA</given-names></name>
<name><surname>Ruhlman</surname> <given-names>MK</given-names></name>
<name><surname>Baxter</surname> <given-names>BT</given-names></name>
</person-group>. 
<article-title>Inflammatory cell phenotypes in AAAS: their role and potential as targets for therapy</article-title>. <source>Arterioscler Thromb Vasc Biol</source>. (<year>2015</year>) <volume>35</volume>:<page-range>1746&#x2013;55</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1161/atvbaha.115.305269</pub-id>, PMID: <pub-id pub-id-type="pmid">26044582</pub-id>
</mixed-citation>
</ref>
<ref id="B14">
<label>14</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Gao</surname> <given-names>J</given-names></name>
<name><surname>Cao</surname> <given-names>H</given-names></name>
<name><surname>Hu</surname> <given-names>G</given-names></name>
<name><surname>Wu</surname> <given-names>Y</given-names></name>
<name><surname>Xu</surname> <given-names>Y</given-names></name>
<name><surname>Cui</surname> <given-names>H</given-names></name>
<etal/>
</person-group>. 
<article-title>The mechanism and therapy of aortic aneurysms</article-title>. <source>Signal Transduct Target Ther</source>. (<year>2023</year>) <volume>8</volume>:<fpage>55</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41392-023-01325-7</pub-id>, PMID: <pub-id pub-id-type="pmid">36737432</pub-id>
</mixed-citation>
</ref>
<ref id="B15">
<label>15</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Sagan</surname> <given-names>A</given-names></name>
<name><surname>Mikolajczyk</surname> <given-names>TP</given-names></name>
<name><surname>Mrowiecki</surname> <given-names>W</given-names></name>
<name><surname>MacRitchie</surname> <given-names>N</given-names></name>
<name><surname>Daly</surname> <given-names>K</given-names></name>
<name><surname>Meldrum</surname> <given-names>A</given-names></name>
<etal/>
</person-group>. 
<article-title>T cells are dominant population in human abdominal aortic aneurysms and their infiltration in the perivascular tissue correlates with disease severity</article-title>. <source>Front Immunol</source>. (<year>2019</year>) <volume>10</volume>:<elocation-id>1979</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fimmu.2019.01979</pub-id>, PMID: <pub-id pub-id-type="pmid">31552015</pub-id>
</mixed-citation>
</ref>
<ref id="B16">
<label>16</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Zhang</surname> <given-names>L</given-names></name>
<name><surname>Wang</surname> <given-names>Y</given-names></name>
</person-group>. 
<article-title>B lymphocytes in abdominal aortic aneurysms</article-title>. <source>Atherosclerosis</source>. (<year>2015</year>) <volume>242</volume>:<page-range>311&#x2013;7</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2015.07.036</pub-id>, PMID: <pub-id pub-id-type="pmid">26233918</pub-id>
</mixed-citation>
</ref>
<ref id="B17">
<label>17</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Spinosa</surname> <given-names>MD</given-names></name>
<name><surname>Montgomery</surname> <given-names>WG</given-names></name>
<name><surname>Lempicki</surname> <given-names>M</given-names></name>
<name><surname>Srikakulapu</surname> <given-names>P</given-names></name>
<name><surname>Johnsrude</surname> <given-names>MJ</given-names></name>
<name><surname>McNamara</surname> <given-names>CA</given-names></name>
<etal/>
</person-group>. 
<article-title>B cell-activating factor antagonism attenuates the growth of experimental abdominal aortic aneurysm</article-title>. <source>Am J Pathol</source>. (<year>2021</year>) <volume>191</volume>:<page-range>2231&#x2013;44</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.ajpath.2021.08.012</pub-id>, PMID: <pub-id pub-id-type="pmid">34509440</pub-id>
</mixed-citation>
</ref>
<ref id="B18">
<label>18</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Yu</surname> <given-names>H</given-names></name>
<name><surname>Jiao</surname> <given-names>X</given-names></name>
<name><surname>Lv</surname> <given-names>Q</given-names></name>
<name><surname>Li</surname> <given-names>L</given-names></name>
<name><surname>Du</surname> <given-names>Y</given-names></name>
<name><surname>Hu</surname> <given-names>C</given-names></name>
<etal/>
</person-group>. 
<article-title>Atf4 contributes to abdominal aortic aneurysm formation via modulating M1 macrophage polarization and inflammation</article-title>. <source>Aging Dis</source>. (<year>2024</year>) <volume>16</volume>:<page-range>1691&#x2013;708</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.14336/ad.2024.0116</pub-id>, PMID: <pub-id pub-id-type="pmid">38913045</pub-id>
</mixed-citation>
</ref>
<ref id="B19">
<label>19</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Song</surname> <given-names>H</given-names></name>
<name><surname>Yang</surname> <given-names>Y</given-names></name>
<name><surname>Sun</surname> <given-names>Y</given-names></name>
<name><surname>Wei</surname> <given-names>G</given-names></name>
<name><surname>Zheng</surname> <given-names>H</given-names></name>
<name><surname>Chen</surname> <given-names>Y</given-names></name>
<etal/>
</person-group>. 
<article-title>Circular rna cdyl promotes abdominal aortic aneurysm formation by inducing M1 macrophage polarization and M1-type inflammation</article-title>. <source>Mol Ther</source>. (<year>2022</year>) <volume>30</volume>:<page-range>915&#x2013;31</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.ymthe.2021.09.017</pub-id>, PMID: <pub-id pub-id-type="pmid">34547461</pub-id>
</mixed-citation>
</ref>
<ref id="B20">
<label>20</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Ortega</surname> <given-names>R</given-names></name>
<name><surname>Collado</surname> <given-names>A</given-names></name>
<name><surname>Selles</surname> <given-names>F</given-names></name>
<name><surname>Gonzalez-Navarro</surname> <given-names>H</given-names></name>
<name><surname>Sanz</surname> <given-names>MJ</given-names></name>
<name><surname>Real</surname> <given-names>JT</given-names></name>
<etal/>
</person-group>. 
<article-title>Sglt-2 (Sodium-glucose cotransporter 2) inhibition reduces Ang ii (Angiotensin ii)-induced dissecting abdominal aortic aneurysm in ApoE (Apolipoprotein E) knockout mice</article-title>. <source>Arterioscler Thromb Vasc Biol</source>. (<year>2019</year>) <volume>39</volume>:<page-range>1614&#x2013;28</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1161/atvbaha.119.312659</pub-id>, PMID: <pub-id pub-id-type="pmid">31294626</pub-id>
</mixed-citation>
</ref>
<ref id="B21">
<label>21</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Hou</surname> <given-names>N</given-names></name>
<name><surname>Zhou</surname> <given-names>H</given-names></name>
<name><surname>Li</surname> <given-names>J</given-names></name>
<name><surname>Xiong</surname> <given-names>X</given-names></name>
<name><surname>Deng</surname> <given-names>H</given-names></name>
<name><surname>Xiong</surname> <given-names>S</given-names></name>
</person-group>. 
<article-title>Macrophage polarization and metabolic reprogramming in abdominal aortic aneurysm</article-title>. <source>Immun Inflammation Dis</source>. (<year>2024</year>) <volume>12</volume>:<fpage>e1268</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/iid3.1268</pub-id>, PMID: <pub-id pub-id-type="pmid">39530309</pub-id>
</mixed-citation>
</ref>
<ref id="B22">
<label>22</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Dale</surname> <given-names>MA</given-names></name>
<name><surname>Xiong</surname> <given-names>W</given-names></name>
<name><surname>Carson</surname> <given-names>JS</given-names></name>
<name><surname>Suh</surname> <given-names>MK</given-names></name>
<name><surname>Karpisek</surname> <given-names>AD</given-names></name>
<name><surname>Meisinger</surname> <given-names>TM</given-names></name>
<etal/>
</person-group>. 
<article-title>Elastin-derived peptides promote abdominal aortic aneurysm formation by modulating M1/M2 macrophage polarization</article-title>. <source>J Immunol</source>. (<year>2016</year>) <volume>196</volume>:<page-range>4536&#x2013;43</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.4049/jimmunol.1502454</pub-id>, PMID: <pub-id pub-id-type="pmid">27183603</pub-id>
</mixed-citation>
</ref>
<ref id="B23">
<label>23</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Yuan</surname> <given-names>Z</given-names></name>
<name><surname>Shu</surname> <given-names>L</given-names></name>
<name><surname>Fu</surname> <given-names>J</given-names></name>
<name><surname>Yang</surname> <given-names>P</given-names></name>
<name><surname>Wang</surname> <given-names>Y</given-names></name>
<name><surname>Sun</surname> <given-names>J</given-names></name>
<etal/>
</person-group>. 
<article-title>Single-cell rna sequencing deconstructs the distribution of immune cells within abdominal aortic aneurysms in mice</article-title>. <source>Arterioscler Thromb Vasc Biol</source>. (<year>2024</year>) <volume>44</volume>:<fpage>1986</fpage>&#x2013;<lpage>2003</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1161/atvbaha.124.321129</pub-id>, PMID: <pub-id pub-id-type="pmid">39051127</pub-id>
</mixed-citation>
</ref>
<ref id="B24">
<label>24</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Shimizu</surname> <given-names>K</given-names></name>
<name><surname>Shichiri</surname> <given-names>M</given-names></name>
<name><surname>Libby</surname> <given-names>P</given-names></name>
<name><surname>Lee</surname> <given-names>RT</given-names></name>
<name><surname>Mitchell</surname> <given-names>RN</given-names></name>
</person-group>. 
<article-title>Th2-predominant inflammation and blockade of ifn-gamma signaling induce aneurysms in allografted aortas</article-title>. <source>J Clin Invest</source>. (<year>2004</year>) <volume>114</volume>:<page-range>300&#x2013;8</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1172/jci19855</pub-id>, PMID: <pub-id pub-id-type="pmid">15254597</pub-id>
</mixed-citation>
</ref>
<ref id="B25">
<label>25</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Lindholt</surname> <given-names>JS</given-names></name>
<name><surname>Shi</surname> <given-names>GP</given-names></name>
</person-group>. 
<article-title>Chronic inflammation, immune response, and infection in abdominal aortic aneurysms</article-title>. <source>Eur J Vasc Endovasc Surg</source>. (<year>2006</year>) <volume>31</volume>:<page-range>453&#x2013;63</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.ejvs.2005.10.030</pub-id>, PMID: <pub-id pub-id-type="pmid">16414293</pub-id>
</mixed-citation>
</ref>
<ref id="B26">
<label>26</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Ocana</surname> <given-names>E</given-names></name>
<name><surname>Boh&#xf3;rquez</surname> <given-names>JC</given-names></name>
<name><surname>P&#xe9;rez-Requena</surname> <given-names>J</given-names></name>
<name><surname>Brieva</surname> <given-names>JA</given-names></name>
<name><surname>Rodr&#xed;guez</surname> <given-names>C</given-names></name>
</person-group>. 
<article-title>Characterisation of T and B lymphocytes infiltrating abdominal aortic aneurysms</article-title>. <source>Atherosclerosis</source>. (<year>2003</year>) <volume>170</volume>:<fpage>39</fpage>&#x2013;<lpage>48</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/s0021-9150(03)00282-x</pub-id>, PMID: <pub-id pub-id-type="pmid">12957681</pub-id>
</mixed-citation>
</ref>
<ref id="B27">
<label>27</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Chang</surname> <given-names>TW</given-names></name>
<name><surname>Gracon</surname> <given-names>AS</given-names></name>
<name><surname>Murphy</surname> <given-names>MP</given-names></name>
<name><surname>Wilkes</surname> <given-names>DS</given-names></name>
</person-group>. 
<article-title>Exploring autoimmunity in the pathogenesis of abdominal aortic aneurysms</article-title>. <source>Am J Physiol Heart Circ Physiol</source>. (<year>2015</year>) <volume>309</volume>:<page-range>H719&#x2013;27</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1152/ajpheart.00273.2015</pub-id>, PMID: <pub-id pub-id-type="pmid">26116712</pub-id>
</mixed-citation>
</ref>
<ref id="B28">
<label>28</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Caligiuri</surname> <given-names>G</given-names></name>
<name><surname>Rossignol</surname> <given-names>P</given-names></name>
<name><surname>Julia</surname> <given-names>P</given-names></name>
<name><surname>Groyer</surname> <given-names>E</given-names></name>
<name><surname>Mouradian</surname> <given-names>D</given-names></name>
<name><surname>Urbain</surname> <given-names>D</given-names></name>
<etal/>
</person-group>. 
<article-title>Reduced immunoregulatory cd31+ T cells in patients with atherosclerotic abdominal aortic aneurysm</article-title>. <source>Arterioscler Thromb Vasc Biol</source>. (<year>2006</year>) <volume>26</volume>:<page-range>618&#x2013;23</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1161/01.ATV.0000200380.73876.d9</pub-id>, PMID: <pub-id pub-id-type="pmid">16357310</pub-id>
</mixed-citation>
</ref>
<ref id="B29">
<label>29</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Meher</surname> <given-names>AK</given-names></name>
<name><surname>Johnston</surname> <given-names>WF</given-names></name>
<name><surname>Lu</surname> <given-names>G</given-names></name>
<name><surname>Pope</surname> <given-names>NH</given-names></name>
<name><surname>Bhamidipati</surname> <given-names>CM</given-names></name>
<name><surname>Harmon</surname> <given-names>DB</given-names></name>
<etal/>
</person-group>. 
<article-title>B2 cells suppress experimental abdominal aortic aneurysms</article-title>. <source>Am J Pathol</source>. (<year>2014</year>) <volume>184</volume>:<page-range>3130&#x2013;41</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.ajpath.2014.07.006</pub-id>, PMID: <pub-id pub-id-type="pmid">25194661</pub-id>
</mixed-citation>
</ref>
<ref id="B30">
<label>30</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Schaheen</surname> <given-names>B</given-names></name>
<name><surname>Downs</surname> <given-names>EA</given-names></name>
<name><surname>Serbulea</surname> <given-names>V</given-names></name>
<name><surname>Almenara</surname> <given-names>CC</given-names></name>
<name><surname>Spinosa</surname> <given-names>M</given-names></name>
<name><surname>Su</surname> <given-names>G</given-names></name>
<etal/>
</person-group>. 
<article-title>B-cell depletion promotes aortic infiltration of immunosuppressive cells and is protective of experimental aortic aneurysm</article-title>. <source>Arterioscler Thromb Vasc Biol</source>. (<year>2016</year>) <volume>36</volume>:<page-range>2191&#x2013;202</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1161/atvbaha.116.307559</pub-id>, PMID: <pub-id pub-id-type="pmid">27634836</pub-id>
</mixed-citation>
</ref>
<ref id="B31">
<label>31</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Furusho</surname> <given-names>A</given-names></name>
<name><surname>Aoki</surname> <given-names>H</given-names></name>
<name><surname>Ohno-Urabe</surname> <given-names>S</given-names></name>
<name><surname>Nishihara</surname> <given-names>M</given-names></name>
<name><surname>Hirakata</surname> <given-names>S</given-names></name>
<name><surname>Nishida</surname> <given-names>N</given-names></name>
<etal/>
</person-group>. 
<article-title>Involvement of B cells, immunoglobulins, and syk in the pathogenesis of abdominal aortic aneurysm</article-title>. <source>J Am Heart Assoc</source>. (<year>2018</year>) <volume>7</volume>:<elocation-id>e007750</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1161/jaha.117.007750</pub-id>, PMID: <pub-id pub-id-type="pmid">29545260</pub-id>
</mixed-citation>
</ref>
<ref id="B32">
<label>32</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>M&#xe1;rquez-S&#xe1;nchez</surname> <given-names>AC</given-names></name>
<name><surname>Koltsova</surname> <given-names>EK</given-names></name>
</person-group>. 
<article-title>Immune and inflammatory mechanisms of abdominal aortic aneurysm</article-title>. <source>Front Immunol</source>. (<year>2022</year>) <volume>13</volume>:<elocation-id>989933</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fimmu.2022.989933</pub-id>, PMID: <pub-id pub-id-type="pmid">36275758</pub-id>
</mixed-citation>
</ref>
<ref id="B33">
<label>33</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Schutyser</surname> <given-names>E</given-names></name>
<name><surname>Struyf</surname> <given-names>S</given-names></name>
<name><surname>Van Damme</surname> <given-names>J</given-names></name>
</person-group>. 
<article-title>The cc chemokine ccl20 and its receptor ccr6</article-title>. <source>Cytokine Growth Factor Rev</source>. (<year>2003</year>) <volume>14</volume>:<page-range>409&#x2013;26</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/s1359-6101(03)00049-2</pub-id>, PMID: <pub-id pub-id-type="pmid">12948524</pub-id>
</mixed-citation>
</ref>
<ref id="B34">
<label>34</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Li</surname> <given-names>Y</given-names></name>
<name><surname>Li</surname> <given-names>R</given-names></name>
<name><surname>Li</surname> <given-names>Y</given-names></name>
<name><surname>Li</surname> <given-names>G</given-names></name>
<name><surname>Zhao</surname> <given-names>Y</given-names></name>
<name><surname>Mou</surname> <given-names>H</given-names></name>
<etal/>
</person-group>. 
<article-title>Transcription factor tcf3 promotes macrophage-mediated inflammation and mmp secretion in abdominal aortic aneurysm by regulating mir-143-5p/ccl20</article-title>. <source>J Cardiovasc Pharmacol</source>. (<year>2023</year>) <volume>82</volume>:<page-range>458&#x2013;69</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1097/fjc.0000000000001484</pub-id>, PMID: <pub-id pub-id-type="pmid">37721971</pub-id>
</mixed-citation>
</ref>
<ref id="B35">
<label>35</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Calvayrac</surname> <given-names>O</given-names></name>
<name><surname>Rodr&#xed;guez-Calvo</surname> <given-names>R</given-names></name>
<name><surname>Alonso</surname> <given-names>J</given-names></name>
<name><surname>Orbe</surname> <given-names>J</given-names></name>
<name><surname>Mart&#xed;n-Ventura</surname> <given-names>JL</given-names></name>
<name><surname>Guadall</surname> <given-names>A</given-names></name>
<etal/>
</person-group>. 
<article-title>Ccl20 is increased in hypercholesterolemic subjects and is upregulated by ldl in vascular smooth muscle cells: role of nf-Kb</article-title>. <source>Arterioscler Thromb Vasc Biol</source>. (<year>2011</year>) <volume>31</volume>:<page-range>2733&#x2013;41</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1161/atvbaha.111.235721</pub-id>, PMID: <pub-id pub-id-type="pmid">21852561</pub-id>
</mixed-citation>
</ref>
<ref id="B36">
<label>36</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Hou</surname> <given-names>L</given-names></name>
<name><surname>Yuki</surname> <given-names>K</given-names></name>
</person-group>. 
<article-title>Ccr6 and cxcr6 identify the th17 cells with cytotoxicity in experimental autoimmune encephalomyelitis</article-title>. <source>Front Immunol</source>. (<year>2022</year>) <volume>13</volume>:<elocation-id>819224</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fimmu.2022.819224</pub-id>, PMID: <pub-id pub-id-type="pmid">35178050</pub-id>
</mixed-citation>
</ref>
<ref id="B37">
<label>37</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Wan</surname> <given-names>W</given-names></name>
<name><surname>Murphy</surname> <given-names>PM</given-names></name>
</person-group>. 
<article-title>Regulation of atherogenesis by chemokine receptor ccr6</article-title>. <source>Trends Cardiovasc Med</source>. (<year>2011</year>) <volume>21</volume>:<page-range>140&#x2013;4</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.tcm.2012.04.003</pub-id>, PMID: <pub-id pub-id-type="pmid">22732549</pub-id>
</mixed-citation>
</ref>
<ref id="B38">
<label>38</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Armas-Gonz&#xe1;lez</surname> <given-names>E</given-names></name>
<name><surname>Dom&#xed;nguez-Luis</surname> <given-names>MJ</given-names></name>
<name><surname>D&#xed;az-Mart&#xed;n</surname> <given-names>A</given-names></name>
<name><surname>Arce-Franco</surname> <given-names>M</given-names></name>
<name><surname>Castro-Hern&#xe1;ndez</surname> <given-names>J</given-names></name>
<name><surname>Danelon</surname> <given-names>G</given-names></name>
<etal/>
</person-group>. 
<article-title>Role of cxcl13 and ccl20 in the recruitment of B cells to inflammatory foci in chronic arthritis</article-title>. <source>Arthritis Res Ther</source>. (<year>2018</year>) <volume>20</volume>:<fpage>114</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1186/s13075-018-1611-2</pub-id>, PMID: <pub-id pub-id-type="pmid">29880013</pub-id>
</mixed-citation>
</ref>
<ref id="B39">
<label>39</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Bruneau</surname> <given-names>S</given-names></name>
<name><surname>Nakayama</surname> <given-names>H</given-names></name>
<name><surname>Woda</surname> <given-names>CB</given-names></name>
<name><surname>Flynn</surname> <given-names>EA</given-names></name>
<name><surname>Briscoe</surname> <given-names>DM</given-names></name>
</person-group>. 
<article-title>Deptor regulates vascular endothelial cell activation and proinflammatory and angiogenic responses</article-title>. <source>Blood</source>. (<year>2013</year>) <volume>122</volume>:<page-range>1833&#x2013;42</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1182/blood-2013-03-488486</pub-id>, PMID: <pub-id pub-id-type="pmid">23881914</pub-id>
</mixed-citation>
</ref>
<ref id="B40">
<label>40</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Manthey</surname> <given-names>HD</given-names></name>
<name><surname>Cochain</surname> <given-names>C</given-names></name>
<name><surname>Barnsteiner</surname> <given-names>S</given-names></name>
<name><surname>Karshovska</surname> <given-names>E</given-names></name>
<name><surname>Pelisek</surname> <given-names>J</given-names></name>
<name><surname>Koch</surname> <given-names>M</given-names></name>
<etal/>
</person-group>. 
<article-title>Ccr6 selectively promotes monocyte mediated inflammation and atherogenesis in mice</article-title>. <source>Thromb Haemost</source>. (<year>2013</year>) <volume>110</volume>:<page-range>1267&#x2013;77</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1160/th13-01-0017</pub-id>, PMID: <pub-id pub-id-type="pmid">24114205</pub-id>
</mixed-citation>
</ref>
<ref id="B41">
<label>41</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Wan</surname> <given-names>W</given-names></name>
<name><surname>Lim</surname> <given-names>JK</given-names></name>
<name><surname>Lionakis</surname> <given-names>MS</given-names></name>
<name><surname>Rivollier</surname> <given-names>A</given-names></name>
<name><surname>McDermott</surname> <given-names>DH</given-names></name>
<name><surname>Kelsall</surname> <given-names>BL</given-names></name>
<etal/>
</person-group>. 
<article-title>Genetic deletion of chemokine receptor ccr6 decreases atherogenesis in apoe-deficient mice</article-title>. <source>Circ Res</source>. (<year>2011</year>) <volume>109</volume>:<page-range>374&#x2013;81</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1161/circresaha.111.242578</pub-id>, PMID: <pub-id pub-id-type="pmid">21680896</pub-id>
</mixed-citation>
</ref>
<ref id="B42">
<label>42</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>S&#xe9;n&#xe9;maud</surname> <given-names>J</given-names></name>
<name><surname>Caligiuri</surname> <given-names>G</given-names></name>
<name><surname>Etienne</surname> <given-names>H</given-names></name>
<name><surname>Delbosc</surname> <given-names>S</given-names></name>
<name><surname>Michel</surname> <given-names>JB</given-names></name>
<name><surname>Coscas</surname> <given-names>R</given-names></name>
</person-group>. 
<article-title>Translational relevance and recent advances of animal models of abdominal aortic aneurysm</article-title>. <source>Arterioscler Thromb Vasc Biol</source>. (<year>2017</year>) <volume>37</volume>:<page-range>401&#x2013;10</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1161/atvbaha.116.308534</pub-id>, PMID: <pub-id pub-id-type="pmid">28062500</pub-id>
</mixed-citation>
</ref>
<ref id="B43">
<label>43</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Hao</surname> <given-names>Y</given-names></name>
<name><surname>Hao</surname> <given-names>S</given-names></name>
<name><surname>Andersen-Nissen</surname> <given-names>E</given-names></name>
<name><surname>Mauck</surname> <given-names>WM</given-names> <suffix>3rd</suffix></name>
<name><surname>Zheng</surname> <given-names>S</given-names></name>
<name><surname>Butler</surname> <given-names>A</given-names></name>
<etal/>
</person-group>. 
<article-title>Integrated analysis of multimodal single-cell data</article-title>. <source>Cell</source>. (<year>2021</year>) <volume>184</volume>:<fpage>3573</fpage>&#x2013;<lpage>87.e29</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.cell.2021.04.048</pub-id>, PMID: <pub-id pub-id-type="pmid">34062119</pub-id>
</mixed-citation>
</ref>
<ref id="B44">
<label>44</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>McGinnis</surname> <given-names>CS</given-names></name>
<name><surname>Murrow</surname> <given-names>LM</given-names></name>
<name><surname>Gartner</surname> <given-names>ZJ</given-names></name>
</person-group>. 
<article-title>Doubletfinder: doublet detection in single-cell rna sequencing data using artificial nearest neighbors</article-title>. <source>Cell Syst</source>. (<year>2019</year>) <volume>8</volume>:<fpage>329</fpage>&#x2013;<lpage>37.e4</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.cels.2019.03.003</pub-id>, PMID: <pub-id pub-id-type="pmid">30954475</pub-id>
</mixed-citation>
</ref>
<ref id="B45">
<label>45</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Wang</surname> <given-names>W</given-names></name>
<name><surname>Cen</surname> <given-names>Y</given-names></name>
<name><surname>Lu</surname> <given-names>Z</given-names></name>
<name><surname>Xu</surname> <given-names>Y</given-names></name>
<name><surname>Sun</surname> <given-names>T</given-names></name>
<name><surname>Xiao</surname> <given-names>Y</given-names></name>
<etal/>
</person-group>. 
<article-title>ScCDC: a computational method for gene-specific contamination detection and correction in single-cell and single-nucleus RNA-seq data</article-title>. <source>Genome Biol</source>. (<year>2024</year>) <volume>25</volume>:<fpage>136</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1186/s13059-024-03284-w</pub-id>, PMID: <pub-id pub-id-type="pmid">38783325</pub-id>
</mixed-citation>
</ref>
<ref id="B46">
<label>46</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Zhang</surname> <given-names>L</given-names></name>
<name><surname>Yu</surname> <given-names>X</given-names></name>
<name><surname>Zheng</surname> <given-names>L</given-names></name>
<name><surname>Zhang</surname> <given-names>Y</given-names></name>
<name><surname>Li</surname> <given-names>Y</given-names></name>
<name><surname>Fang</surname> <given-names>Q</given-names></name>
<etal/>
</person-group>. 
<article-title>Lineage tracking reveals dynamic relationships of T cells in colorectal cancer</article-title>. <source>Nature</source>. (<year>2018</year>) <volume>564</volume>:<page-range>268&#x2013;72</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41586-018-0694-x</pub-id>, PMID: <pub-id pub-id-type="pmid">30479382</pub-id>
</mixed-citation>
</ref>
<ref id="B47">
<label>47</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Jin</surname> <given-names>S</given-names></name>
<name><surname>Plikus</surname> <given-names>MV</given-names></name>
<name><surname>Nie</surname> <given-names>Q</given-names></name>
</person-group>. 
<article-title>Cellchat for systematic analysis of cell-cell communication from single-cell transcriptomics</article-title>. <source>Nat Protoc</source>. (<year>2025</year>) <volume>20</volume>:<fpage>180</fpage>&#x2013;<lpage>219</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41596-024-01045-4</pub-id>, PMID: <pub-id pub-id-type="pmid">39289562</pub-id>
</mixed-citation>
</ref>
<ref id="B48">
<label>48</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Ritchie</surname> <given-names>ME</given-names></name>
<name><surname>Phipson</surname> <given-names>B</given-names></name>
<name><surname>Wu</surname> <given-names>D</given-names></name>
<name><surname>Hu</surname> <given-names>Y</given-names></name>
<name><surname>Law</surname> <given-names>CW</given-names></name>
<name><surname>Shi</surname> <given-names>W</given-names></name>
<etal/>
</person-group>. 
<article-title>Limma powers differential expression analyses for rna-sequencing and microarray studies</article-title>. <source>Nucleic Acids Res</source>. (<year>2015</year>) <volume>43</volume>:<fpage>e47</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1093/nar/gkv007</pub-id>, PMID: <pub-id pub-id-type="pmid">25605792</pub-id>
</mixed-citation>
</ref>
<ref id="B49">
<label>49</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Robinson</surname> <given-names>MD</given-names></name>
<name><surname>McCarthy</surname> <given-names>DJ</given-names></name>
<name><surname>Smyth</surname> <given-names>GK</given-names></name>
</person-group>. 
<article-title>Edger: A bioconductor package for differential expression analysis of digital gene expression data</article-title>. <source>Bioinformatics</source>. (<year>2010</year>) <volume>26</volume>:<page-range>139&#x2013;40</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1093/bioinformatics/btp616</pub-id>, PMID: <pub-id pub-id-type="pmid">19910308</pub-id>
</mixed-citation>
</ref>
<ref id="B50">
<label>50</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Yu</surname> <given-names>G</given-names></name>
<name><surname>Wang</surname> <given-names>LG</given-names></name>
<name><surname>Han</surname> <given-names>Y</given-names></name>
<name><surname>He</surname> <given-names>QY</given-names></name>
</person-group>. 
<article-title>Clusterprofiler: an R package for comparing biological themes among gene clusters</article-title>. <source>Omics</source>. (<year>2012</year>) <volume>16</volume>:<page-range>284&#x2013;7</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1089/omi.2011.0118</pub-id>, PMID: <pub-id pub-id-type="pmid">22455463</pub-id>
</mixed-citation>
</ref>
<ref id="B51">
<label>51</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Newman</surname> <given-names>AM</given-names></name>
<name><surname>Liu</surname> <given-names>CL</given-names></name>
<name><surname>Green</surname> <given-names>MR</given-names></name>
<name><surname>Gentles</surname> <given-names>AJ</given-names></name>
<name><surname>Feng</surname> <given-names>W</given-names></name>
<name><surname>Xu</surname> <given-names>Y</given-names></name>
<etal/>
</person-group>. 
<article-title>Robust enumeration of cell subsets from tissue expression profiles</article-title>. <source>Nat Methods</source>. (<year>2015</year>) <volume>12</volume>:<page-range>453&#x2013;7</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/nmeth.3337</pub-id>, PMID: <pub-id pub-id-type="pmid">25822800</pub-id>
</mixed-citation>
</ref>
<ref id="B52">
<label>52</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Sun</surname> <given-names>D</given-names></name>
<name><surname>Guan</surname> <given-names>X</given-names></name>
<name><surname>Moran</surname> <given-names>AE</given-names></name>
<name><surname>Wu</surname> <given-names>LY</given-names></name>
<name><surname>Qian</surname> <given-names>DZ</given-names></name>
<name><surname>Schedin</surname> <given-names>P</given-names></name>
<etal/>
</person-group>. 
<article-title>Identifying phenotype-associated subpopulations by integrating bulk and single-cell sequencing data</article-title>. <source>Nat Biotechnol</source>. (<year>2022</year>) <volume>40</volume>:<page-range>527&#x2013;38</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41587-021-01091-3</pub-id>, PMID: <pub-id pub-id-type="pmid">34764492</pub-id>
</mixed-citation>
</ref>
<ref id="B53">
<label>53</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Zhao</surname> <given-names>G</given-names></name>
<name><surname>Lu</surname> <given-names>H</given-names></name>
<name><surname>Chang</surname> <given-names>Z</given-names></name>
<name><surname>Zhao</surname> <given-names>Y</given-names></name>
<name><surname>Zhu</surname> <given-names>T</given-names></name>
<name><surname>Chang</surname> <given-names>L</given-names></name>
<etal/>
</person-group>. 
<article-title>Single-cell rna sequencing reveals the cellular heterogeneity of aneurysmal infrarenal abdominal aorta</article-title>. <source>Cardiovasc Res</source>. (<year>2021</year>) <volume>117</volume>:<page-range>1402&#x2013;16</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1093/cvr/cvaa214</pub-id>, PMID: <pub-id pub-id-type="pmid">32678909</pub-id>
</mixed-citation>
</ref>
<ref id="B54">
<label>54</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Wang</surname> <given-names>ZY</given-names></name>
<name><surname>Cheng</surname> <given-names>J</given-names></name>
<name><surname>Wang</surname> <given-names>Y</given-names></name>
<name><surname>Yuan</surname> <given-names>HT</given-names></name>
<name><surname>Bi</surname> <given-names>SJ</given-names></name>
<name><surname>Wang</surname> <given-names>SX</given-names></name>
<etal/>
</person-group>. 
<article-title>Macrophage ilf3 promotes abdominal aortic aneurysm by inducing inflammatory imbalance in male mice</article-title>. <source>Nat Commun</source>. (<year>2024</year>) <volume>15</volume>:<fpage>7249</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41467-024-51030-4</pub-id>, PMID: <pub-id pub-id-type="pmid">39179537</pub-id>
</mixed-citation>
</ref>
<ref id="B55">
<label>55</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Soto</surname> <given-names>B</given-names></name>
<name><surname>Gallastegi-Mozos</surname> <given-names>T</given-names></name>
<name><surname>Rodr&#xed;guez</surname> <given-names>C</given-names></name>
<name><surname>Mart&#xed;nez-Gonz&#xe1;lez</surname> <given-names>J</given-names></name>
<name><surname>Escudero</surname> <given-names>JR</given-names></name>
<name><surname>Vila</surname> <given-names>L</given-names></name>
<etal/>
</person-group>. 
<article-title>Circulating ccl20 as a new biomarker of abdominal aortic aneurysm</article-title>. <source>Sci Rep</source>. (<year>2017</year>) <volume>7</volume>:<fpage>17331</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41598-017-17594-6</pub-id>, PMID: <pub-id pub-id-type="pmid">29229985</pub-id>
</mixed-citation>
</ref>
<ref id="B56">
<label>56</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Cai</surname> <given-names>D</given-names></name>
<name><surname>Sun</surname> <given-names>C</given-names></name>
<name><surname>Murashita</surname> <given-names>T</given-names></name>
<name><surname>Que</surname> <given-names>X</given-names></name>
<name><surname>Chen</surname> <given-names>SY</given-names></name>
</person-group>. 
<article-title>Adar1 non-editing function in macrophage activation and abdominal aortic aneurysm</article-title>. <source>Circ Res</source>. (<year>2023</year>) <volume>132</volume>:<page-range>e78&#x2013;93</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1161/circresaha.122.321722</pub-id>, PMID: <pub-id pub-id-type="pmid">36688311</pub-id>
</mixed-citation>
</ref>
<ref id="B57">
<label>57</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Ma</surname> <given-names>Y</given-names></name>
<name><surname>Ding</surname> <given-names>XJ</given-names></name>
<name><surname>Lu</surname> <given-names>SY</given-names></name>
<name><surname>Huang</surname> <given-names>XF</given-names></name>
<name><surname>Hu</surname> <given-names>YY</given-names></name>
<name><surname>Liu</surname> <given-names>H</given-names></name>
<etal/>
</person-group>. 
<article-title>M2 Macrophage-Derived Extracellular Vesicles Protect against Abdominal Aortic Aneurysm by Modulating Macrophage Polarization through Mir221-5p</article-title>. <source>Cell Mol Biol Lett</source>. (<year>2025</year>) <volume>30</volume>:<fpage>96</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1186/s11658-025-00768-w</pub-id>, PMID: <pub-id pub-id-type="pmid">40784924</pub-id>
</mixed-citation>
</ref>
<ref id="B58">
<label>58</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Wu</surname> <given-names>W</given-names></name>
<name><surname>Tang</surname> <given-names>W</given-names></name>
<name><surname>Liang</surname> <given-names>W</given-names></name>
<name><surname>Li</surname> <given-names>Q</given-names></name>
<name><surname>Qi</surname> <given-names>X</given-names></name>
<name><surname>Gao</surname> <given-names>R</given-names></name>
<etal/>
</person-group>. 
<article-title>Gdf15 suppresses abdominal aortic aneurysm by upregulating areg expression to adjust macrophage polarization</article-title>. <source>Int Immunopharmacol</source>. (<year>2025</year>) <volume>159</volume>:<elocation-id>114899</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.intimp.2025.114899</pub-id>, PMID: <pub-id pub-id-type="pmid">40414071</pub-id>
</mixed-citation>
</ref>
<ref id="B59">
<label>59</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Shen</surname> <given-names>L</given-names></name>
<name><surname>Yu</surname> <given-names>J</given-names></name>
<name><surname>Chen</surname> <given-names>W</given-names></name>
<name><surname>Bi</surname> <given-names>Y</given-names></name>
<name><surname>Yang</surname> <given-names>Z</given-names></name>
<name><surname>Lu</surname> <given-names>C</given-names></name>
<etal/>
</person-group>. 
<article-title>Ppp1r3b suppresses atherosclerosis by promoting the M2 polarization of macrophages through glycogen metabolic reprogramming</article-title>. <source>Adv Sci (Weinh)</source>. (<year>2025</year>) <volume>12</volume>, <fpage>e06345</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/advs.202506345</pub-id>, PMID: <pub-id pub-id-type="pmid">40984828</pub-id>
</mixed-citation>
</ref>
<ref id="B60">
<label>60</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Wang</surname> <given-names>J</given-names></name>
<name><surname>Da</surname> <given-names>X</given-names></name>
<name><surname>Chen</surname> <given-names>Y</given-names></name>
<name><surname>Yuan</surname> <given-names>A</given-names></name>
<name><surname>Pu</surname> <given-names>J</given-names></name>
</person-group>. 
<article-title>Glutamine Protects against Mouse Abdominal Aortic Aneurysm through Modulating Vsmc Apoptosis and M1 Macrophage Activation</article-title>. <source>Int J Med Sci</source>. (<year>2024</year>) <volume>21</volume>:<page-range>1414&#x2013;27</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.7150/ijms.96395</pub-id>, PMID: <pub-id pub-id-type="pmid">38903916</pub-id>
</mixed-citation>
</ref>
<ref id="B61">
<label>61</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Wu</surname> <given-names>Z</given-names></name>
<name><surname>Zhang</surname> <given-names>P</given-names></name>
<name><surname>Yue</surname> <given-names>J</given-names></name>
<name><surname>Wang</surname> <given-names>Q</given-names></name>
<name><surname>Zhuang</surname> <given-names>P</given-names></name>
<name><surname>Jehan</surname> <given-names>S</given-names></name>
<etal/>
</person-group>. 
<article-title>Tea polyphenol nanoparticles enable targeted sirna delivery and multi-bioactive therapy for abdominal aortic aneurysms</article-title>. <source>J Nanobiotechnol</source>. (<year>2024</year>) <volume>22</volume>:<fpage>471</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1186/s12951-024-02756-2</pub-id>, PMID: <pub-id pub-id-type="pmid">39118143</pub-id>
</mixed-citation>
</ref>
<ref id="B62">
<label>62</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>King</surname> <given-names>VL</given-names></name>
<name><surname>Lin</surname> <given-names>AY</given-names></name>
<name><surname>Kristo</surname> <given-names>F</given-names></name>
<name><surname>Anderson</surname> <given-names>TJ</given-names></name>
<name><surname>Ahluwalia</surname> <given-names>N</given-names></name>
<name><surname>Hardy</surname> <given-names>GJ</given-names></name>
<etal/>
</person-group>. 
<article-title>Interferon-gamma and the interferon-inducible chemokine cxcl10 protect against aneurysm formation and rupture</article-title>. <source>Circulation</source>. (<year>2009</year>) <volume>119</volume>:<page-range>426&#x2013;35</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1161/circulationaha.108.785949</pub-id>, PMID: <pub-id pub-id-type="pmid">19139386</pub-id>
</mixed-citation>
</ref>
<ref id="B63">
<label>63</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Middleton</surname> <given-names>RK</given-names></name>
<name><surname>Lloyd</surname> <given-names>GM</given-names></name>
<name><surname>Bown</surname> <given-names>MJ</given-names></name>
<name><surname>Cooper</surname> <given-names>NJ</given-names></name>
<name><surname>London</surname> <given-names>NJ</given-names></name>
<name><surname>Sayers</surname> <given-names>RD</given-names></name>
</person-group>. 
<article-title>The pro-inflammatory and chemotactic cytokine microenvironment of the abdominal aortic aneurysm wall: A protein array study</article-title>. <source>J Vasc Surg</source>. (<year>2007</year>) <volume>45</volume>:<page-range>574&#x2013;80</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.jvs.2006.11.020</pub-id>, PMID: <pub-id pub-id-type="pmid">17321344</pub-id>
</mixed-citation>
</ref>
<ref id="B64">
<label>64</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Meitei</surname> <given-names>HT</given-names></name>
<name><surname>Jadhav</surname> <given-names>N</given-names></name>
<name><surname>Lal</surname> <given-names>G</given-names></name>
</person-group>. 
<article-title>Ccr6-ccl20 axis as a therapeutic target for autoimmune diseases</article-title>. <source>Autoimmun Rev</source>. (<year>2021</year>) <volume>20</volume>:<elocation-id>102846</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.autrev.2021.102846</pub-id>, PMID: <pub-id pub-id-type="pmid">33971346</pub-id>
</mixed-citation>
</ref>
<ref id="B65">
<label>65</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Rizas</surname> <given-names>KD</given-names></name>
<name><surname>Ippagunta</surname> <given-names>N</given-names></name>
<name><surname>Tilson</surname> <given-names>MD</given-names> <suffix>3rd</suffix></name>
</person-group>. 
<article-title>Immune cells and molecular mediators in the pathogenesis of the abdominal aortic aneurysm</article-title>. <source>Cardiol Rev</source>. (<year>2009</year>) <volume>17</volume>:<page-range>201&#x2013;10</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1097/CRD.0b013e3181b04698</pub-id>, PMID: <pub-id pub-id-type="pmid">19690470</pub-id>
</mixed-citation>
</ref>
<ref id="B66">
<label>66</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Zhao</surname> <given-names>G</given-names></name>
<name><surname>Cho</surname> <given-names>CS</given-names></name>
<name><surname>Liu</surname> <given-names>H</given-names></name>
<name><surname>Hwang</surname> <given-names>Y</given-names></name>
<name><surname>Si</surname> <given-names>Y</given-names></name>
<name><surname>Kim</surname> <given-names>M</given-names></name>
<etal/>
</person-group>. 
<article-title>Single-cell spatial transcriptomics unravels the cellular landscape of abdominal aortic aneurysm</article-title>. <source>JCI Insight</source>. (<year>2025</year>) <volume>10</volume>:<elocation-id>e190534</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1172/jci.insight.190534</pub-id>, PMID: <pub-id pub-id-type="pmid">40857411</pub-id>
</mixed-citation>
</ref>
<ref id="B67">
<label>67</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Davis</surname> <given-names>FM</given-names></name>
<name><surname>Tsoi</surname> <given-names>LC</given-names></name>
<name><surname>Ma</surname> <given-names>F</given-names></name>
<name><surname>Wasikowski</surname> <given-names>R</given-names></name>
<name><surname>Moore</surname> <given-names>BB</given-names></name>
<name><surname>Kunkel</surname> <given-names>SL</given-names></name>
<etal/>
</person-group>. 
<article-title>Single-cell transcriptomics reveals dynamic role of smooth muscle cells and enrichment of immune cell subsets in human abdominal aortic aneurysms</article-title>. <source>Ann Surg</source>. (<year>2022</year>) <volume>276</volume>:<page-range>511&#x2013;21</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1097/sla.0000000000005551</pub-id>, PMID: <pub-id pub-id-type="pmid">35762613</pub-id>
</mixed-citation>
</ref>
<ref id="B68">
<label>68</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Galle</surname> <given-names>C</given-names></name>
<name><surname>Schanden&#xe9;</surname> <given-names>L</given-names></name>
<name><surname>Stordeur</surname> <given-names>P</given-names></name>
<name><surname>Peignois</surname> <given-names>Y</given-names></name>
<name><surname>Ferreira</surname> <given-names>J</given-names></name>
<name><surname>Wautrecht</surname> <given-names>J-C</given-names></name>
<etal/>
</person-group>. 
<article-title>Predominance of type 1 cd4+T cells in human abdominal aortic aneurysm</article-title>. <source>Clin Exp Immunol</source>. (<year>2005</year>) <volume>142</volume>:<page-range>519&#x2013;27</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1111/j.1365-2249.2005.02938.x</pub-id>, PMID: <pub-id pub-id-type="pmid">16297165</pub-id>
</mixed-citation>
</ref>
<ref id="B69">
<label>69</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Xiong</surname> <given-names>W</given-names></name>
<name><surname>Zhao</surname> <given-names>Y</given-names></name>
<name><surname>Prall</surname> <given-names>A</given-names></name>
<name><surname>Greiner</surname> <given-names>TC</given-names></name>
<name><surname>Baxter</surname> <given-names>BT</given-names></name>
</person-group>. 
<article-title>Key roles of cd4+ T cells and ifn-gamma in the development of abdominal aortic aneurysms in a murine model</article-title>. <source>J&#xa0;Immunol</source>. (<year>2004</year>) <volume>172</volume>:<page-range>2607&#x2013;12</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.4049/jimmunol.172.4.2607</pub-id>, PMID: <pub-id pub-id-type="pmid">14764734</pub-id>
</mixed-citation>
</ref>
<ref id="B70">
<label>70</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Wei</surname> <given-names>Z</given-names></name>
<name><surname>Wang</surname> <given-names>Y</given-names></name>
<name><surname>Zhang</surname> <given-names>K</given-names></name>
<name><surname>Liao</surname> <given-names>Y</given-names></name>
<name><surname>Ye</surname> <given-names>P</given-names></name>
<name><surname>Wu</surname> <given-names>J</given-names></name>
<etal/>
</person-group>. 
<article-title>Inhibiting the th17/il-17a-related inflammatory responses with digoxin confers protection against experimental abdominal aortic aneurysm</article-title>. <source>Arterioscler Thromb Vasc Biol</source>. (<year>2014</year>) <volume>34</volume>:<page-range>2429&#x2013;38</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1161/atvbaha.114.304435</pub-id>, PMID: <pub-id pub-id-type="pmid">25234817</pub-id>
</mixed-citation>
</ref>
<ref id="B71">
<label>71</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Koga</surname> <given-names>T</given-names></name>
<name><surname>Otomo</surname> <given-names>K</given-names></name>
<name><surname>Mizui</surname> <given-names>M</given-names></name>
<name><surname>Yoshida</surname> <given-names>N</given-names></name>
<name><surname>Umeda</surname> <given-names>M</given-names></name>
<name><surname>Ichinose</surname> <given-names>K</given-names></name>
<etal/>
</person-group>. 
<article-title>Calcium/calmodulin-dependent kinase iv facilitates the recruitment of interleukin-17-producing cells to target organs through the ccr6/ccl20 axis in th17 cell-driven inflammatory diseases</article-title>. <source>Arthritis Rheumatol</source>. (<year>2016</year>) <volume>68</volume>:<page-range>1981&#x2013;8</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/art.39665</pub-id>, PMID: <pub-id pub-id-type="pmid">26945541</pub-id>
</mixed-citation>
</ref>
<ref id="B72">
<label>72</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Iida</surname> <given-names>Y</given-names></name>
<name><surname>Xu</surname> <given-names>B</given-names></name>
<name><surname>Xuan</surname> <given-names>H</given-names></name>
<name><surname>Glover</surname> <given-names>KJ</given-names></name>
<name><surname>Tanaka</surname> <given-names>H</given-names></name>
<name><surname>Hu</surname> <given-names>X</given-names></name>
<etal/>
</person-group>. 
<article-title>Peptide inhibitor of cxcl4-ccl5 heterodimer formation, mkey, inhibits experimental aortic aneurysm initiation and progression</article-title>. <source>Arterioscler Thromb Vasc Biol</source>. (<year>2013</year>) <volume>33</volume>:<page-range>718&#x2013;26</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1161/atvbaha.112.300329</pub-id>, PMID: <pub-id pub-id-type="pmid">23288157</pub-id>
</mixed-citation>
</ref>
<ref id="B73">
<label>73</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>de Waard</surname> <given-names>V</given-names></name>
<name><surname>Bot</surname> <given-names>I</given-names></name>
<name><surname>de Jager</surname> <given-names>SC</given-names></name>
<name><surname>Talib</surname> <given-names>S</given-names></name>
<name><surname>Egashira</surname> <given-names>K</given-names></name>
<name><surname>de Vries</surname> <given-names>MR</given-names></name>
<etal/>
</person-group>. 
<article-title>Systemic&#xa0;mcp1/ccr2 blockade and leukocyte specific mcp1/ccr2 inhibition affect aortic aneurysm formation differently</article-title>. <source>Atherosclerosis</source>. (<year>2010</year>) <volume>211</volume>:<page-range>84&#x2013;9</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2010.01.042</pub-id>, PMID: <pub-id pub-id-type="pmid">20197192</pub-id>
</mixed-citation>
</ref>
<ref id="B74">
<label>74</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Moran</surname> <given-names>CS</given-names></name>
<name><surname>Jose</surname> <given-names>RJ</given-names></name>
<name><surname>Moxon</surname> <given-names>JV</given-names></name>
<name><surname>Roomberg</surname> <given-names>A</given-names></name>
<name><surname>Norman</surname> <given-names>PE</given-names></name>
<name><surname>Rush</surname> <given-names>C</given-names></name>
<etal/>
</person-group>. 
<article-title>Everolimus limits aortic aneurysm in the apolipoprotein E-deficient mouse by downregulating C-C chemokine receptor 2 positive monocytes</article-title>. <source>Arterioscler Thromb Vasc Biol</source>. (<year>2013</year>) <volume>33</volume>:<page-range>814&#x2013;21</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1161/atvbaha.112.301006</pub-id>, PMID: <pub-id pub-id-type="pmid">23393391</pub-id>
</mixed-citation>
</ref>
<ref id="B75">
<label>75</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Qun</surname> <given-names>L</given-names></name>
<name><surname>Wenda</surname> <given-names>X</given-names></name>
<name><surname>Weihong</surname> <given-names>S</given-names></name>
<name><surname>Jianyang</surname> <given-names>M</given-names></name>
<name><surname>Wei</surname> <given-names>C</given-names></name>
<name><surname>Fangzhou</surname> <given-names>L</given-names></name>
<etal/>
</person-group>. 
<article-title>Mirna-27b modulates endothelial cell angiogenesis by directly targeting naa15 in atherogenesis</article-title>. <source>Atherosclerosis</source>. (<year>2016</year>) <volume>254</volume>:<page-range>184&#x2013;92</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2016.10.007</pub-id>, PMID: <pub-id pub-id-type="pmid">27755984</pub-id>
</mixed-citation>
</ref>
<ref id="B76">
<label>76</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Lysgaard Poulsen</surname> <given-names>J</given-names></name>
<name><surname>Stubbe</surname> <given-names>J</given-names></name>
<name><surname>Lindholt</surname> <given-names>JS</given-names></name>
</person-group>. 
<article-title>Animal models used to explore abdominal aortic aneurysms: A systematic review</article-title>. <source>Eur J Vasc Endovasc Surg</source>. (<year>2016</year>) <volume>52</volume>:<page-range>487&#x2013;99</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.ejvs.2016.07.004</pub-id>, PMID: <pub-id pub-id-type="pmid">27543385</pub-id>
</mixed-citation>
</ref>
</ref-list>
<fn-group>
<fn id="n1" fn-type="custom" custom-type="edited-by">
<p>Edited by: <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/1696706">Zhirui Zeng</ext-link>, Guizhou Medical University, China</p></fn>
<fn id="n2" fn-type="custom" custom-type="reviewed-by">
<p>Reviewed by: <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/855648">YuFeng Zhang</ext-link>, Nanjing University of Chinese Medicine, China</p>
<p><ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/1608413">Hadjer Namous</ext-link>, Independent Researcher, Madison, WI, United States</p></fn>
</fn-group>
</back>
</article>